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ABSTRACT 
REBECCA BALTER: Access to running wheels attenuates spontaneous 
morphine withdrawal in mice as measured by thermal sensitivity 
(Under the direction of Linda A. Dykstra) 
 
Opioid withdrawal is a critical component of opioid abuse and consists of a 
wide array of symptoms. For many people, the presence of, or desire to avoid, 
these withdrawal symptoms drives continued drug taking. There is growing 
evidence that aerobic exercise may be a positive intervention during the 
withdrawal period. The following studies seek to develop a behavioral procedure 
to examine one component of spontaneous opioid withdrawal in mice, 
hypersensitivity to a thermal stimulus, and to examine the effects of access to a 
running wheel during withdrawal.  The experiments of Chapter 2 describe and 
validate the spontaneous withdrawal procedure. During the first 48 hours 
following the cessation of 30, 56, or 100 mg/kg morphine response latency on a 
hotplate is significantly decreased suggesting an increase in thermal sensitivity. 
The experiments described in Chapter 3 demonstrate that access to a running 
wheel during withdrawal reduced this increase in thermal sensitivity. Chapter 4 
extended the previous results, assessing the effect of a locked wheel and group 
housing during withdrawal. The results provide evidence that use of the wheel 
not simply environmental enrichment maximized the effect on thermal sensitivity. 
The experiments of Chapter 5 sought to further probe the effects of wheel access.  
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Morphine’s potency was assessed following 6 weeks of wheel access or chronic 
morphine injections. Under both conditions, tolerance to the antinociceptive 
effects of morphine developed. Immediately following behavioral testing, changes 
in the expression of five genes associated with the opioid system was assessed 
using qRT-PCR.  The experimental results descried in this dissertation suggest 
that thermal sensitivity is a reliable and sensitive measure of spontaneous 
morphine withdrawal in mice and that wheel access can attenuate this sign of 
withdrawal.  
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Chapter 1 
 
General Introduction 
 
[Helen] quickly dropped into the wine they were enjoying     
a drug which eased men’s pains and irritations, 
making them forget their troubles. 
Odyssey IV:220-221  
 
It is widely assumed that the pain-easing drug referred to by Homer was 
an opium-based preparation.   Centuries later, Edgar Allen Poe references the 
drug by its Greek descriptor in his poem “The Raven”, summoning its abilities to 
ease the mind: "Let me quaff this kind Nepenthe and forget this lost Lenore!" 
Despite all of the advances of modern medicine, morphine and its derivatives are 
still some of the most effective analgesics for many types of clinical pain.  
Unfortunately, the opioid’s ability to ease the pain of the spirit ensures that it is 
often abused as well.   
Conservatively, 2-6% of patients prescribed long-term opioids and up to 
30% of illicit users develop drug dependence (Christie, 2008).  This dependence 
is often driven by the ease and degree to which tolerance to opioids can form. 
Long-term illicit opioid users report consumption of doses up to a hundred fold 
higher than acutely effective doses (Stanford et al., 2004). Consistent 
consumption of such high doses often leads to physical dependence and the 
appearance of withdrawal symptoms when drug taking is terminated.  For many 
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people, the presence of, or desire to avoid, these withdrawal symptoms drives 
continued drug taking (Le Moal and Koob, 2007).  Consequently, understanding 
and treating opioid withdrawal is a critical component of treating opioid abuse.  
This dissertation presents the rationale and results from a series of studies that 
1) developed a behavioral procedure to examine one component of opioid 
withdrawal, i.e., hypersensitivity to a thermal stimulus, 2) examined the effects of 
access to a running wheel on withdrawal following the development of morphine 
tolerance and 3) examined changes in gene expression and morphine sensitivity 
following chronic access to a running wheel.  
 
The opioid receptors: expression and anatomy 
 To date, three opioid receptors have been identified: mu, kappa, and 
delta. The mu-opioid receptor, named for its stereotypical ligand morphine, 
shows the broadest distribution and is found throughout the brain and spinal cord.  
The highest concentrations can be found in the striatum, nucleus accumbens, 
amygdala, periaqueductal grey, and locus coeruleus (Daunais et al., 2001; 
McClung 2006; McDonald and Lambert 2005).   
Extensive research suggests that activity in the nucleus accumbens is 
responsible for the reinforcing properties of opioids (Carlezon and Wise, 1996; 
Einstein et al., 2013; Pettit et al., 1984; Shippenberg et al., 1992; Spyraki et al., 
1983; Stinus et al., 1989).   Activity in the nucleus accumbens is likely driven by 
opioid induced excitation of dopaminergic neurons in the ventral tegmental area 
through the hyperpolarization of local inhibitory GABA-ergic interneurons 
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(Johnson and North, 1992). However, there is also evidence to support 
dopamine-independent mechanisms of reinforcement in the nucleus accumbens 
(Koob and Volkow, 2010).   
Stimulation of the periaqueductal grey (PAG) through mu as well as kappa 
and delta opioid receptor activity is predominantly responsible for the analgesic 
effects of the opioids.  Specifically, enkephalin-releasing neurons of the PAG can 
trigger the release of serotonin from the raphe nuclei which in turn can activate 
inhibitory neurons in the dorsal root ganglia reducing afferent nociceptive 
signaling (see Ossipov et al., 2010 for a review). The PAG as well as the locus 
coeruleus also play critical roles in opioid withdrawal and will be discussed in 
more detail later.  
 Kappa-opioid receptors are most highly expressed in the periaqueductal 
grey, locus coeruleus and amygdala as well as in the hypothalamus (McClung 
2006; Mansour et al., 1995; Knoll et al., 2011).  Expression in the basal lateral 
and central amaygdala seems to be of particular importance in mediating the 
anxiolytic effects of kappa-opioid receptor antagonists (Knoll et al., 2011). Finally, 
the highest density of delta-opioid receptors is found in the striatum, nucleus 
accumbens, olfactory bulb and cerebral cortex (McDonald and Lambert, 2005).  
Expression throughout the mesolimbic dopamine pathway may provide a neural 
substrate for the observed anti-depressive effects of delta receptor agonists 
(Jutkiewicz and Roques, 2012).  
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The opioid receptors: cellular activity 
 All three of the opioid receptors belong to a superfamily of 7-
transmembrane G-protein coupled receptors (GPCR’s) and are predominately 
found postsynaptically on dendrites and cell bodies of neurons (Ding et al., 1996).   
 Agonist binding of the receptors triggers the release of the alpha subunit 
of the coupled Gi/Go proteins (Pennock and Hentges, 2011).  The “i” of Gi 
references their inhibitory downstream effects. First, opioid-activated G-proteins 
can activate inward rectifying potassium channels, hyperpolarizing the cell and 
decreasing the probability of an action potential (Kelly et al., 1990; Law et al., 
2000). Neuron excitation is also reduced through decreased conductance of 
voltage gated Ca2+ channels (Childers, 1991). Second, the G-proteins can inhibit 
adenylate cyclase activity, which leads to a decrease in cyclic AMP, PKA and 
phosphorylated CREB ultimately decreasing the expression of many genes 
including cFos, tyrosine hydroxylase, and corticotropin releasing factor (CRF) 
(McClung, 2006). 
 
The opioid receptors: chronic activation and tolerance 
 In addition to immediate inhibitory effects on the neuron, agonist binding 
induces the intracellular phosphorylation of the opioid receptor by GPCR kinases 
(GIRK’s) (Koch and Holt, 2008). The first effect of phosphorylation is a transient 
desensitization to further activation (Narita et al. 1995, Ueda et al 1995).  
Phosphorylation also increases the affinity of the receptor for beta-arrestin. Once 
bound, beta-arrestin accelerates the uncoupling of the receptor from its G-protein 
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further desensitizing the receptor, possibly through MEK/ERK pathways (Bohn et 
al., 2000; Connor et al., 2004; Williams et al., 2013). Finally, beta-arrestin 
facilitates receptor internalization through its association with clathrin (Koch and 
Hollt, 2008).  This arrestin-mediated internalization is a critical first step in the 
resensitization and recycling of receptors back to the cell surface (Koch and Hollt, 
2008) 
It is important to note that desensitization does not always lead to 
internalization.  In particular, morphine produces strong receptor desensitization 
but fails to promote efficient internalization and consequent resensitization (Bohn 
et al., 2004).  By contrast, DAMGO (a synthetic endorphin), triggers strong 
internalization (Connor et al., 2004). In general, it appears that the relative ability 
of opioids to induce endocytosis is inversely correlated with their ability to induce 
opioid tolerance (Williams et al., 2013).  This relative ability is sometimes referred 
to as an agonist’s RAVE value (Relative Activation Versus Endocytosis) (Martini 
and Whistler, 2007).  This somewhat heuristic model suggests that agonists with 
a high RAVE value (high activation, little endocytosis) like morphine have 
increased potential to produce tolerance and dependence (Whistler et al. 1999). 
As tolerance develops following chronic opioid receptor activation, 
adenylate cyclase becomes superactivated to compensate for extended inhibition, 
allowing depressed cAMP levels to return to normal (Koch and Holt, 2008; Watts 
and Neve, 2005). It is likely that tolerance is also mediated by circuit level 
mechanisms as indicated by the role of the NMDA receptor in the formation of 
tolerance (Dykstra et al., 2011).  These are a few of the most studied 
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mechanisms that contribute to tolerance, however, it is clear that no single 
mechanism can account for the massive degree of opioid tolerance that is often 
observed. 
 
Opioid withdrawal: cellular mechanisms 
Newton’s third law of motion states that “to every action there is always an 
equal and opposite reaction”.  Though far from the realm of 18th century physics, 
this quite elegantly describes the theoretical framework for drug withdrawal.  In 
the field of substance abuse, the opponent-process theory suggests that 
withdrawal is the product of an equal but opposite response to its foil, tolerance 
(Radke et al., 2011).  Chronic drug exposure requires the establishment of a set 
of physiological parameters far outside the normal homeostatic range in order to 
maintain systemic stability (Sterling and Ever, 1988).  This state of chronic 
deviation, consisting of all of the changes that allow for drug tolerance, is the 
allostatic state (Koob and LeMoal, 2001).     
 Consistent with the allostasis theory, opioid withdrawal is likely the result 
of hyper-excitation of brain regions and cellular processes that were chronically 
inhibited during extended opioid exposure. On a cellular level, cessation of opioid 
exposure should produce an increase in the phosphorylation of CREB via 
hyperactivity of sensitized adenylate cyclase (Nestler and Aghajanian, 1997; 
Sharma et al., 1975).  Morphine withdrawal dependent increases in 
phosphorylated CREB have in fact been seen in both the hypothalamus and 
nucleus accumbens (Li et al., 2010; Martin et al. 2011).   
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 Of the various genes whose expression is under the control of CREB, 
corticotropin-releasing factor or CRF may be the most important.   Suppression 
of CRF signaling to both the amygdala and nucleus accumbens can attenuate 
morphine withdrawal symptoms (Almela et al., 2012; Heinrichs et al., 1995; 
McNally and Akil, 2002).  Additionally, CRF signaling can trigger an increase in 
dynorphin expression in the nucleus accumbens, which contributes to the 
negative affective state of withdrawal (Contarino and Papaleo, 2005). Finally, 
aside from the pituitary gland, the locus coeruleus is probably the most important 
afferent structure for hypothalamic CRF signaling.   Activation of the locus 
coeruleus causes the release of norepinephrine which drives the “fight or flight” 
state produced by the sympathetic branch of the central nervous system 
(McClung, 2006; Brodal, 2004).  Not surprisingly, many of the bodily responses 
associated with sympathetic activation are also symptoms seen during opioid 
withdrawal (e.g. elevated pulse, sweating, pupil dilation).  
 In the drug –naïve brain, endogenous opioids play an inhibitory role and 
counterbalance the excitatory effects of CRF on the locus coeruleus-
norepinephrine system (Curtis et al., 2001); chronic opiate administration is 
thought to sensitize locus coeruleus neurons to the effects of CRF (Xu, 04).   The 
cessation of exogenous opioid administration unveils the full effects of CRF 
activation of the sensitized noradrenergic system (Curtis et al., 1997). 
 Although the locus coeruleus clearly plays an important role in opioid 
withdrawal, it is not necessary for opioid withdrawal.  Caille et al. (1999) 
precipitated morphine withdrawal in rats with almost complete lesions of the 
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locus coeruleus.  They and others conclude that opioid withdrawal also requires 
action in the anatomically adjacent periaqueductal grey (see review by Christie et 
al., 1997).  
In fact, chronic morphine infusions directly into the periaqueductal grey 
(PAG) are sufficient to produce physical dependence in rats (Bozarth and Wise 
1984).  Once dependent, infusions of an opioid antagonist into the animal’s PAG 
can precipitate withdrawal (Maldonado et al., 1992).  Furthermore, morphine 
withdrawal triggers an increase in PAG expression of enkephalins, likely through 
activation of the cAMP/CREB pathway (Folkesson et al., 1989).  Interestingly, 
infusions of enkephalin analogs into the PAG will suppress both precipitated and 
spontaneous withdrawal, suggesting that the PAG may also be a site of 
modulation of withdrawal (Fukunaga and Kishioka, 2000).  Finally, opioid 
withdrawal is associated with rebounds in GABA-ergic signaling in the PAG 
(Hack et al., 2003). 
 
Opioid withdrawal: experimental evaluation 
Humans 
 Opioid withdrawal has been measured in many ways, most commonly 
by examining a range of physical symptoms (Wesson and Ling, 2003).  The first 
withdrawal scale was published by Lawrence Kolb and C.K. Himmelsback in 
1938 in the Journal of Clinical Psychiatry.  A revised version from 1941 is often 
cited as the Himmelsback scale.  More recently, Handelsman et al. (1987) 
developed a pair of scales to assess the subjective and objective symptoms; the 
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Subjective Opiate Withdrawal Scale (SOWS) and Objective Opiate Withdrawal 
Scale (OOWS).  In 1990, a new SOWS, the short opioid withdrawal scale, was 
developed by Gossop.  It includes 10 measures of both objective and subjective 
symptoms: feeling sick, stomach cramps, muscle spasms/twitching, feeling of 
coldness, heart pounding, muscular tension, aches and pains, yawning, runny 
eyes, and insomnia.  The format was slightly modified by Wesson and Ling 
(2003) to produce the current clinical opiate withdrawal scale (COWS) which 
includes eleven measures of objective and subjective symptoms.   These scales 
have been used by both researchers and health care professionals (e.g. Chu et 
al., 2009; Tompkins et al., 2009; Umbricht et al., 2003).  In addition to multi-
symptom scale, many studies have used changes in body temperature, heart 
rate and pain sensitivity (hyperalgeisa) to assess withdrawal (Himmelsbach, 
1942; Martin and Jasinski, 1969). Hyperalgeis in particular has been reported 
during spontaneous withdrawal in pain patients in experimental settings (Lipman 
and Blumenkopf, 1989) as well as in case studies (Devulder et al., 1996). 
Additionally, healthy human subjects show hyperalgesia during both 
spontaneous (Angst et al., 2003) and antagonist precipitated withdrawal 
(Compton et al., 2003; Sun, 1998). 
 
Non-human Primates 
Concurrent with the initial development of opioid withdrawal scales for 
humans was the development of the first withdrawal scale tailored to non-human 
primates (Seevers, 1936).  Seevers’ scale included a wide range of symptoms 
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quite similar to those seen in humans indicative of mild (yawning, shivering, 
hiccups, etc), moderate (tremor, anorexia, cramps, etc) and severe withdrawal 
(vomiting, diarrhea, insomnia, crying, etc).  Variations of this scale have been 
used to assess withdrawal in the decades since (e.g. Deneau and Seevers, 
1963; Holtzman and Villarreal, 1969; Sell et al., 2005). In addition to somatic 
symptoms, a number of research groups have used changes in operant 
responding to assess opioid withdrawal.  One approach, measures disruption in 
food reinforced responding to quantify withdrawal (e.g. Thompson and 
Schuster,1964; Holtzman and Villarreal, 1973). A second approach uses drug 
discrimination to identify interoceptive withdrawal states in which naltrexone is 
used as the discriminative stimulus (Brandt and France, 1998; Becker et al., 
2008; France and Woods, 1989; McMahon et al., 2009). 
 
Rodents 
The majority of rodent studies assess opioid withdrawal by measuring the 
presence of behavioral signs such as jumping, wet dog shakes, piloerection, 
diarrhea, writhing, and ptosis  (e.g. Kest et al., 2002; Papaleo and Contarino 
2006).  An alternative approach assesses changes in body temperature, heart 
rate, and blood pressure (Froger-Colleaux et al., 2011) Though some studies 
consider a single sign of withdrawal, most use a weighted scale adapted from the 
first global rodent scale described by Gellert and Holtzman (1978). Such an 
approach mimics the withdrawal scales used in humans and primates. Although 
many symptoms are consistent across species such as tremors, diarrhea and 
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piloerection (goose bumps), one of the most striking behaviors, jumping, is 
unique to rodents.  Jumping during opioid withdrawal was first described in 1969 
in a paper by Way et al.  Although the original procedure measured the number 
of rats that jumped off a platform, recent experiments measure the number of 
times a mouse or rat jumps when contained inside a beaker or activity chamber.  
Beyond somatic signs of withdrawal, conditioned place aversion is often 
used to evaluate the aversive state produced during withdrawal (e.g. Gómez-
Milanés et al., 2012; Wang et al., 2012).  The elevated plus maze, open field test, 
and Morris water maze can also be used to assess the cognitive and anxiogenic 
effects of withdrawal (Miladi-Gorji et al., 2011, 2012).  Although these 
approaches are excellent for answering many questions, they are limited in their 
ability to measure subtle changes during withdrawal produced by behavioral 
interventions. Many of the somatic signs appear in a binary present/absent 
dichotomy.  Conditioned place aversion and cognitive measures may provide 
more subtle data but are limited to precipitated withdrawal and are sensitive to 
repeated testing, respectively.   
Hyperalgesia, another measure of withdrawal, was first presented by 
Tilson et al. in 1973.  They reported that sensitivity to electric foot shock 
increases following the cessation of chronic morphine in rats.  Like many of the 
somatic symptoms, hyperalgesia has translational validity considering that “an 
increase in pain or sensitivity to pain” is one of the symptoms that make up the 
Clinical Opiate Withdrawal Scale, used to assess withdrawal in humans.   
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Since Tilson’s 1973 study, a modest number of papers have described 
hyperalgesia in animal models of opioid withdrawal.  In rats, hyperalgesia occurs 
during both precipitated and spontaneous morphine withdrawal (Devillers et al., 
1995; Dunbar and Pulai, 1998; Grilly and Gowans, 1986; Jin et al., 2012; Li et al., 
2001).  Hyperalgesia in rats also occurs during withdrawal from other opioids 
such as fentanyl (Laulin et al., 2002) and heroin (Devillers et al., 1995; Laulin et 
al., 1998).   
 To the best of our knowledge only two prior studies employ a 
hyperalgesia model for examining opioid withdrawal in mice.  Rubovich et al. 
(2009) examine only a single time point during spontaneous withdrawal and 
Crain and Shen (2007) employ a precipitated withdrawal procedure.  
 
Opioid withdrawal: existing treatments  
As stated previously, for many people, the presence or desire to avoid 
withdrawal symptoms will drive continued drug taking (Le Moal and Koob, 2007). 
As such, having effective treatments for withdrawal is a critical component of 
addiction treatment.   In the 1960’s, the introduction of methadone replacement 
therapies revolutionized the treatment of opioid addiction by providing an 
effective pharmacological intervention. Though methadone is still the primary 
long-term treatment for opioid dependence, there is increasing support for 
buprenorphine, a low efficacy mu agonist, as an alternative agonist replacement 
therapy (e.g. Connock et al., 2007; Kraus et al., 2011).  The primary advantages 
of buprenorphine are its greatly decreased risk of respiratory depression and its 
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ability to suppress spontaneous opioid withdrawal symptoms during the induction 
phase of treatment (Strain et al., 2011).  Additionally the anxiolytic, clonidine, and 
the opiate antagonist naloxone are approved as detoxification treatments 
(Nicholls et al., 2010).   
Though these treatments are highly effective, they all have unwanted 
effects including constipation, nausea and respiratory depression (Fiellin et al., 
2002).  Additionally some methadone maintained patients still report cue-induced 
cravings that increase the risk of relapse (Fareed et al., 2011). Finally, there are 
always questions about potential abuse and/or diversion of these compounds.   
 
Improving existing treatments 
The American Psychological Association, as well as most treatment 
programs, emphasizes the fact that treatment effectiveness is optimized when 
pharmacological interventions are combined with psychosocial approaches.  At 
the present time, there is growing interest and evidence for exercise as a positive 
behavioral intervention for optimizing the treatment of drug addiction.   
Specifically, it has been reported that short periods of aerobic exercise 
can decrease the desire for alcohol (Ussher et al., 2004), tobacco (Taylor and 
Katomeri, 2007) and cannabis (Buchowski et al., 2011) in humans.  Exercise has 
also been shown to reduce symptoms of nicotine withdrawal and aids in smoking 
cessation (Taylor and Ussher, 2005; Taylor and Katomeri, 2007).  
Rodents with access to running wheels reduce their self-administration of 
amphetamine (Kanarek et al., 1995), heroin (Smith and Pitts, 2012) and alcohol 
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(Hammer et al., 2010) and show a decrease in morphine conditioned place 
preference (Lett et al., 2002).  Beyond altering acute drug effects, limited 
evidence from the animal literature suggests that voluntary wheel running is 
beneficial during drug withdrawal. For example, wheel running attenuates 
seizures induced by ethanol withdrawal (Devaud et al., 2012) and reduces 
cognitive deficits and anxiety associated with spontaneous morphine withdrawal 
in rats (Miladi-Gorji et al., 2011, 2012).  
It is possible that these behavioral effects are due to increases in levels of 
endogenous opiates following aerobic exercise.  In humans, beta- endorphin 
levels increase three-fold following treadmill exercise (Mahler et al., 2009) and 
pain sensitivity decreases following rowing exercise (Cohen et al., 2010). 
In animals, many studies have shown that wheel running can produce 
rightward shifts in a morphine dose-effect curve (Kanarek et al., 1998; Mathes 
and Kanarek, 2001; Smith and Yancey 2003; Smith and Lyle, 2006). Opioid-like 
withdrawal has even been precipitated after chronic exercise in rats (Kanarek et 
al., 2009).  Taken together, these studies provide evidence that wheel running 
can alter the functioning of the opiate system. 
  
Goals of this dissertation 
The primary hypothesis of this dissertation is the following: The severity of 
spontaneous morphine withdrawal, as measured by hypersensitivity to a thermal 
stimulus, is reduced in mice that are given access to running wheels in their 
home cages. Aim I (described in Chapter II) addresses the first step in testing 
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this hypothesis by developing and validating a sensitive measure of spontaneous 
morphine withdrawal in mice.  Aim II (described in Chapters III and IV) directly 
tests the primary hypothesis that wheel access reduces withdrawal severity and 
examines potential mechanisms for the effect. Aim III (described in Chapter V) 
further addresses the mechanism by which wheel access alters brain and 
behavior by comparing the effects of chronic wheel access with those of chronic 
morphine.   
 
Aim I:  Thermal sensitivity, measured by response latency on a hot plate, is a 
sensitive measure of spontaneous morphine withdrawal in mice. 
Aim I validated the use of thermal sensitivity as a measure of spontaneous 
morphine withdrawal. To test this hypothesis, physical dependence was induced 
by 5.5 days of twice daily injections of 56 mg/kg morphine.  At multiple time 
points following the final injection, withdrawal was assessed in two ways. First, 
thermal sensitivity was evaluated by latency to respond on the hot plate at a 
range of temperatures (50, 52, 54 and 56oC).  Second, within and between 
subject changes in thermal sensitivity were compared to changes in jumping 
behavior.  The ability of a dose of buprenorphine to attenuate withdrawal-induced 
changes in thermal sensitivity was also tested. 
 
Aim II: Access to a running wheel in the home cage attenuates increases in 
thermal sensitivity observed during spontaneous morphine withdrawal in mice.  
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To test this hypothesis, mice were given morphine injections for 5.5 days 
to establish physical dependence. Following termination of this chronic regimen, 
mice were given access to running wheels throughout the subsequent withdrawal 
period. Withdrawal was measured by determining thermal sensitivity on the hot 
plate at baseline and at 8, 24, 32, 48 hrs and 1 week following termination of the 
chronic regimen of morphine administration.  
Aim II examined these effects further by determining the effects of wheel 
access on morphine withdrawal under conditions in which running wheels were 
present in the mice cages, but were in a “locked” position. Since mice were 
housed singly in the experiments involving access to a running wheel, an 
additional set of experiments examined the effects of group housing on morphine 
withdrawal.  
 
Aim III:  Chronic wheel access reduces morphine’s antinociceptive potency and 
produces changes in gene expression that are similar to changes seen following 
chronic morphine administration.   
The behavioral portion of this aim used the tail-flick procedure to assess 
morphine’s antinociceptive effects.  Research in our laboratory, as well as in 
many others, has shown that morphine’s antinociceptive effects in the tail-flick 
procedure are dose-dependent and reliable (Fisher et al., 2005; 2008). Moreover, 
the development of tolerance following chronic administration of morphine can be 
readily observed with the tail-flick procedure (e.g. Huidobro, 1971; Kamei et al., 
1973; Fernandes et al., 1977; Bhargava, 1978). Therefore, the effects of chronic 
17 
 
morphine in the tail-flick procedure were compared to the effects of access to 
running wheels.  
 The second section of Aim III used quantitative polymerase chain reaction 
(qPCR) to compare gene expression following chronic wheel access and chronic 
morphine administration.  The expression of five genes was assessed: POMC, 
PENK, PDYN, MOR1, and ARRB2.  Proopiomelanocortin (POMC), 
proenkephalin (PENK) and prodynorphin (PDYN) were selected because they 
code for the precursor proteins that are post-translationally modified into the 
three major endogenous opioids: beta-endorphin, enkephalin, and dynorphin, 
(Aghajanian and Sanders-Bush 2002). MOR1 gene codes for the mu-opioid 
receptor (Ammon-Treiber et al 2005). Beta-arrestin 2 (BARR2) encodes the 
protein beta-arrestin which regulates mu-opioid receptor desensitization and 
internalization (Bohn et al., 2004).  Gene expression was assessed in four brain 
regions integral to the formation and expression of morphine tolerance: the 
striatum, nucleus accumbens, hypothalamus and periaqueductal grey. 
Together, these experiments will support the use of a new method to 
evaluate spontaneous morphine withdrawal and extend our knowledge of the 
effects of wheel running during withdrawal.  Ultimately, these studies carry great 
translational potential to support the use of aerobic exercise in the treatment of 
opioid addiction.
 Chapter 2 
Thermal sensitivity as a measure of spontaneous morphine withdrawal in 
mice 
 
INTRODUCTION 
 
The opioid withdrawal syndrome consists of a constellation of symptoms 
that appear following the termination of a prolonged period of opioid 
administration. The presence or desire to avoid these symptoms may even 
contribute to continued drug taking (Le Moal and Koob, 2007).  As such, 
withdrawal is a critical component of opioid abuse. One of the many symptoms 
that make up the Clinical Opiate Withdrawal Scale or COWS (Tompkins et al., 
2009) is an increase in pain or sensitivity to pain.  An increase in pain sensitivity 
or hyperalgesia during spontaneous withdrawal occurs in pain patients in 
experimental settings (Lipman and Blumenkopf, 1989) and is reported in case 
studies, as well (Devulder et al., 1996). Healthy human subjects show 
hyperalgesia during both spontaneous (Angst et al 2003) and antagonist 
precipitated withdrawal (Compton et al., 2003; Sun, 1998). 
The development of pharmacological and environmental interventions to 
mitigate hyperalgesia during opioid withdrawal requires reliable preclinical 
models of this symptom of withdrawal. In 1973, Tilson et al. reported that 
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sensitivity to electric foot shock increases following the cessation of morphine in 
rats.  Since then a modest number of papers have described hyperalgesia in 
animal models of opioid withdrawal.  In rats, hyperalgesia occurs during both 
precipitated as well as spontaneous morphine withdrawal and is observed with 
multiple pain assays: hot plate, tail-flick, and shock discrimination (Devillers et al., 
1995; Dunbar and Pulai 1998; Grilly and Gowans 1986; Jin et al., 2012; Li et al., 
2001; Tilson et al., 1973).  Hyperalgesia in rats also occurs during withdrawal 
from fentanyl (Laulin et al., 2002) and heroin (Devillers et al., 1995; Laulin et al., 
1998).  Beyond rodents, withdrawal hypersensitivity is seen in both dogs (Martin 
et al., 1987) and cats (Johnson and Duggan, 1981).   
Traditionally, opioid withdrawal in mice is measured by the presence of 
behavioral signs such as jumping, wet dog shakes, piloerection, diarrhea, and 
ptosis (e.g. Kest et al., 2002; Papaleo and Contarino 2006).  To the best of our 
knowledge only two studies from laboratories other than our own employ a 
hyperalgesia model for examining opioid withdrawal in mice.  These studies 
examine only a single time point during spontaneous withdrawal (Rubovich et al., 
2009) or employ a precipitated, rather than a spontaneous, withdrawal procedure 
(Crain and Shen 2007).  
The current study describes a new method for assessing hyperalgesia in a 
mouse model of spontaneous morphine withdrawal.  We hypothesize that 
thermal sensitivity on a hot plate will increase during spontaneous withdrawal 
from a range of morphine doses.  Further, we hypothesize that buprenorphine 
treatment during the withdrawal period will attenuate the increase in sensitivity. 
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Buprenorphine, a low efficacy mu agonist, was selected because it is commonly 
used in agonist replacement therapy for opioid dependence (e.g. Connock et al. 
2007 and Kraus et al., 2011), and used to suppress spontaneous opioid 
withdrawal symptoms during the induction phase of treatment (Strain et al. 2011). 
 
METHODS 
Animals 
All experiments were conducted in male C57BL/6J mice (Jackson Labs, 
Raleigh, NC), 10 weeks of age upon delivery. Male C57BL/6J mice were 
selected to allow comparison with other data collected in our laboratory regarding 
morphine’s pharmacological effects as well as the extensive literature on the 
behavioral effects of opioids in C57BL/6 mice. Additionally, in comparison to 
other inbred strains, C57BL/6J mice are known to be highly sensitive across 
many behavioral assays.  Specifically, they exhibit high sensitivity in measures of 
acute nociception (Mogil et al., 2000), naloxone precipitated morphine withdrawal 
(Kest et al. 2002) and morphine self-administration (Elmer et al. 2009).  
Mice were individually housed in polycarbonate cages (floor area=335cm2) 
with continuous access to food and water throughout the study. The colony room 
was maintained on a 12-hr, reverse, light/dark cycle (lights off at 7:00 am) and all 
behavioral testing was conducted during the dark cycle, between 9:00 am and 
7:00 pm. Mice were habituated to handling and the colony room environment for 
two weeks prior to any experimental manipulation. Mice were also exposed to the 
testing environment for at least two days prior to initiation of an experiment and 
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for 1 hr prior to all behavioral testing. Although a criterion was set such that mice 
<20 g or those that lost >20% of initial body weight would be removed from the 
study, it was not necessary to remove any mice from the study.  Animal protocols 
were approved by the Institutional Animal Care and Use Committee, and the 
methods were in accord with the “Guide for the Care and Use of Laboratory 
Animals” (Institute of Laboratory Animal Research, Commission on Life Sciences, 
National Research Council, 2011). 
 
Experimental Procedures 
Thermal Sensitivity: Thermal sensitivity was assessed using a hot plate 
analgesia meter (25.3 × 25.3 cm), Columbus Instruments, Columbus, OH.  
During each 1-hr hot plate testing period, a temperature-effect curve was 
determined for each mouse.  Sensitivity was evaluated by recording the latency 
to lick or flutter the hind paw(s), or to jump from the hot plate surface at each of 
four temperatures presented in the following order: 50, 54, 52, 56oC with 15-min 
intervals between temperatures.  Response latency was measured to the nearest 
0.1 sec. To prevent tissue damage, a predetermined cutoff time of 20 sec was 
defined as the maximal trial duration. Immediately following the termination of a 
trial, whether due to a mouse’s response or elapsed cutoff time, mice were 
removed from the hot plate surface. Parameters were selected based on prior 
work in our laboratory regarding responses on the hot plate (e.g. Fischer et al. 
2008; Balter and Dykstra, 2012). 
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Jumping: To measure jumping, mice were removed from their home cages 
and placed in a 4L beaker in the center of a Med Associates Inc. activity chamber.  
Vertical beam breaks, monitored by a computer, were used to count the number 
of jumps that occurred in a 30-min period.   
 
Pharmacological Procedure: During the saline/morphine administration 
period, doses of saline, 30 mg/kg, 56 mg/kg or 100 mg/kg of morphine were 
administered daily for 5.5 days, with injections occurring at 10:00 am and 8:00 
pm daily (11 injections total). Morphine sulfate and buprenorphine hydrochloride, 
provided by the National Institute on Drug Abuse (Bethesda, MD, USA), were 
both dissolved in 0.9% saline to yield all concentrations. Doses were injected 
subcutaneously at a volume of 0.1 ml /10 g. 
 
Experimental Design 
Experiment 1: Thermal sensitivity following saline, 30, 56, or 100 mg/kg of 
morphine 
On day one, thermal sensitivity was assessed in all four groups of mice 
(n=8) at 10:00 am (baseline 1) and at 6:00 pm (baseline 2).  A 2-way repeated 
measures ANOVA revealed no difference between baseline 1 and baseline 2; 
therefore, baselines were averaged for all analyses and figures. At 10:00 am on 
day two 30, 56, 100 mg/kg morphine or saline administration began as described 
above and continued for 5.5 days. Following the last dose of morphine on day 
seven, thermal sensitivity was assessed six more times: immediately after the 
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final injection (10:00 am on day 7), at 8 hrs (6:00 pm on day 7), at 24 hrs (10:00 
am on day 8), at 32 hrs (6:00 pm on day 8), at 48 hrs (10:00 am on day 9) and at 
1 week (10:00 am on day 14). This period (days 7-14) was designated as the 
withdrawal period.  
 
Experiment 2: Buprenorphine and thermal sensitivity 
In order to select a dose of buprenorphine that did not produce 
antinociception on its own, a cumulative dose-effect curve (0.01 to 0.32 mg/kg) 
was obtained for buprenorphine at each of the four temperatures tested during 
the thermal sensitivity assessment (50, 52, 54 and 56 ±0.1oC). Baseline 
response latencies on the hot plate were determined twice prior to the beginning 
of the buprenorphine dose-effect curve and spaced 30 min apart. Data from 
these baselines were averaged to yield one baseline value. Following baseline 
determination, responding on the hot plate was examined over multiple cycles, 
and doses of buprenorphine were spaced 30 min apart. Drugs were administered 
at the start of each cycle and latency on the hot place was determined during the 
last minute of the cycle. Drug doses were increased cumulatively, with the dose 
increasing in one-half log unit increments prior to each cycle (0.01, 0.03, 0.1, 
0.32 mg/kg). Buprenorphine effects were expressed as a percentage of the 
maximal possible effect (% MPE) using the following formula: 
                [Postdrug latency - baseline latency] 
%MPE= ---------------------------------------------------- 
               [cutoff time (20sec) - baseline latency] 
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During the withdrawal experiment, on day one thermal sensitivity was 
assessed in two groups of mice (n=8) at 10:00 am (baseline 1) and 6:00 pm 
(baseline 2).  A 2-way repeated measures ANOVA revealed no difference 
between baseline 1 and baseline 2; therefore, baselines were averaged for all 
analyses and figures. At 10:00 am on day two 56 mg/kg morphine administration 
began for all mice as described above and continued for 5.5 days. Following the 
last dose of morphine on day seven, thermal sensitivity was assessed five more 
times: immediately after the final injection (10:00 am on day 7), at 8 hrs (6:00 pm 
on day 7), at 24 hrs (10:00 am on day 8), at 32 hrs (6:00 pm on day 8), and at 48 
hrs (10:00 am on day 9). A dose of 0.01 mg/kg buprenorphine or saline was 
administered subcutaneously 30 minutes prior to each testing session on days 7-
9.  This period (days 7-9) was designated as the withdrawal period.  
 
Experiment 3: Jumping responses following saline, 30, 56, or 100 mg/kg of 
morphine 
On day one, jumping was assessed in all four groups of mice (n=8) at 
10:00 am (baseline 1, AM) and at 6:00 pm (baseline 1, PM). One week later on 
day 8, a second baseline measure (baseline 2, AM and PM) was taken at 10:00 
am and 6:00 pm.  The second set of baselines (10:00 am and 6:00 pm on day 8) 
was used for data analysis. At 10:00 am on day nine 30, 56, 100 mg/kg morphine 
or saline administration began as described above and continued for 5.5 days. 
Following the last dose of morphine on day 14, thermal sensitivity was assessed 
five more times: immediately after the final injection (10:00am on day 14), at 8 
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hrs (6:00 pm on day 14), at 24 hrs (10:00 am on day 15), at 32 hrs (6:00 pm on 
day 15), at 48 hrs (10:00 am on day 16). This period (days 14-16) was 
designated as the withdrawal period.  
 
Data analysis 
  All data are presented as means (+SEM).  In Experiments I and II, 
response latencies were used to derive a measure of thermal sensitivity, 
designated as ET10. The ET10 represents the theoretical temperature required 
to produce a response latency of 10 sec (half the maximal response latency of 20 
sec) and was derived using log-linear interpolation.  In Experiment III, jumping 
responses during the withdrawal period are presented and analyzed as jumps 
during the withdrawal period minus the average number of jumps that occurred 
during the corresponding baseline period (i.e., Since data for the 0, 24, and 48 
hrs withdrawal period fell in the AM, baseline measures from the morning period 
were used.  Likewise since data for the 8 and 36 hrs withdrawal period fell in the 
PM, baseline measures from the evening period were used.)  
Analysis of the latency data used a 3-way repeated measures ANOVA 
with time and temperature as repeated measures factors and group as an 
independent factor. ET10 and jumping data were analyzed using a 2-way 
repeated measures ANOVA with time as the repeated measures factor and 
group as an independent factor. For the 2- and 3-way ANOVA, an alpha level of 
significance was set at p<0.01.  Following the 3-way ANOVA, appropriate follow-
up contrasts and Student’s t-tests were performed using a fully saturated mixed 
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model of the data.  The model was a straight model of the means and included 
random intercepts for each mouse.  Following the 2-way ANOVAs, appropriate 
follow-up contrasts were performed using a model of jumps or ET10 as a function 
of time and group.  The null hypothesis assumed no mean difference in the 
number of jumps or the ET10 values. Standard error was adjusted for multiple 
observations within each mouse. 
Statistical analyses were conducted with an alpha level of significance set 
at p<0.001. The alpha level was determined using Bonferoni corrections to 
account for the large number of comparisons.  The ANOVAs were performed 
using SPSS for Windows software, version 9.0.  All post hoc analysis was 
performed using SAS for Windows software, version 9.2.  Figures were created 
with GraphPad Prism 5. 
 
RESULTS 
 
Thermal sensitivity following spontaneous withdrawal from 30, 56, or 100 
mg/kg morphine.  
Fig. 2.1 shows the latency to respond on the hot plate as a function of 
temperature at baseline, 8, 24, 32, 48 hrs and 1 wk following termination of the 
5.5 day treatment period of either 30, 56, or 100 mg/kg morphine or saline.  In 
general, two findings were consistent across all time points.  First, latency to 
respond on the hot plate decreased as a function of temperature.  Response 
latencies in both saline and morphine-treated mice were at or close to the 
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maximal value of 20 sec when the hot plate was set at 50oC; at 52, 54 and 56oC, 
latencies averaged 12.8, 9.4 and 5.7 sec, respectively. Second, response 
latencies at the 0 (data not shown), 8, 24, 32 and 48-hr and 1 wk time points for 
saline-treated mice were never significantly different from baseline, calculated as 
the average of baseline 1 and 2, indicating that repetition of testing did not 
produce measurable effects on response latency.  In addition, immediately 
following the final morphine injection (0 hr), response latencies were at the cut off 
value of 20 sec at all temperatures for morphine-treated mice; consequently 
these data are not shown.  The failure to respond within in the 20 sec maximal 
trial duration indicates a full antinociceptive response to acute morphine 
exposure. 
 A 3-way repeated measures ANOVA revealed a time x temperature x 
group interaction F(45, 405) = 1.974, p<0.001. Follow up Student’s t-tests were 
then used to compare individual groups, time points, and temperatures.  
 In general, the curves obtained in the morphine-treated mice were 
displaced downward from those obtained at baseline and from those of saline-
treated mice.   Significant differences in response latencies were apparent 
between morphine-treated and saline- treated mice throughout the withdrawal 
period.  Significant differences between the 30 mg/kg morphine- and saline-
treated mice were apparent at 32 and 48 hrs (52oC) t621= 3.87, 4.43, p<0.001, 
respectively. Significant differences between the 56 mg/kg morphine- and saline-
treated mice were apparent at 8 hrs (52oC) t621= 3.41, p<0.001; 24 hrs (52 and 
54oC) t621= 6.13, 5.25, p<0.001; 32 hrs (50, 52, 54
oC) t621=6.12, 4.96, 5.13, 
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p<0.001; 48 hrs (50, 52, 54oC) t621=3.65, 6.787, 3.82, p<0.001; and at 1 wk (50 
and 54oC) t621=3.45, 3.55, p<0.001.  Significant differences between the 100 
mg/kg morphine- and saline-treated mice were apparent at 48 hrs (50 and 52oC) 
t621= 4.30, 5.21, p<0.001 and at 1 wk (50, 52, 54
oC) t621= 6.51, 5.85, 4.37, 
p<0.001. In addition, the responses of morphine-treated mice were significantly 
different from baseline at all points where responses were different from those of 
saline-treated mice.  These differences suggest that mice treated with 30, 56, or 
100 mg/kg of morphine for 5.5 days and then withdrawn from morphine were 
more sensitive to the thermal stimulus than mice treated with saline.  
It is also important to note significant differences in response latency 
between different morphine treated groups during the withdrawal period.  
Response latencies of mice treated with 56 mg/kg morphine were significantly 
different from those of mice treated with 30 mg/kg morphine at 8hrs and 24hrs 
(52oC) t621=3.31, 3.70, p<0.001, respectively and at 32 hrs (50
oC) t621=5.32, 
p<0.001.  Response latencies in mice treated with 56 mg/kg morphine were also 
significantly different from response latencies obtained in mice treated with 100 
mg/kg morphine at 8hrs and 24hrs (52oC) t621=4.08, 3.44, p<0.001, respectively 
and at 32 hrs (50oC) t621=4.43, p<0.001.   Finally, a significant difference in 
response latencies was apparent between mice treated with 100 mg/kg and 30 
mg/kg morphine at 1 wk (50 and 52oC) t621=5.66, 4.02, p<0.001.   
Taken together, these data suggest that 5.5 days of morphine treatment 
was sufficient to produce significant changes in thermal sensitivity compared to 
both within-subject baselines and saline controls.  However, the dose of 
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morphine (30, 56, or 100 mg/kg) affected the extent and time course of this 
response, with the greatest changes in latency observed following 56 mg/kg 
morphine and at 32 hrs into the withdrawal period.   
Fig. 2.2 shows the ET10 value at baseline, 8, 24, 32, 48 hrs and 1 wk 
following termination of the 5.5-day treatment period with either 30, 56, 100 
mg/kg morphine or saline. The ET10 values were derived from the data shown in 
Fig. 2.1.  They represent the theoretical temperature necessary to produce a 10 
sec response on the hot plate.  A 2-way repeated measures ANOVA revealed a 
main effect of time F(5, 135) = 2.299, p<0.05.  Individual groups and time points 
were compared using appropriate follow up contrasts.  For mice treated with 30 
mg/kg morphine, a significant difference in ET10 value compared to baseline was 
apparent at 32 and 48 hrs, t133=3.42, 4.30, p<0.001, respectively. For mice 
treated with 56 mg/kg morphine, a significant difference in ET10 value compared 
to baseline was apparent at 24, 32, 48 hrs and 1 wk, t133=5.45, 6.74, 4.97, 3.97, 
p<0.001, respectively.  At each of these time points (24, 32, 48 hrs and 1 wk), the 
ET10 values of mice treated with 56 mg/kg morphine were also significantly 
different from those of saline-treated mice, t133=4.46, 5.37, 3.91, 3.52, p<0.001, 
respectively. For mice treated with 100 mg/kg morphine, a significant difference 
in ET10 value compared to baseline was apparent at 32, 48 hrs and 1 wk, 
t133=3.64, 6.89, 8.29, p<0.001, respectively.  The ET10 values of mice treated 
with 100 mg/kg morphine were also significantly different from those of saline-
treated mice at 48 hrs and 1 wk, t133=5.16, 6.75, p<0.001, respectively.  There 
were no significant differences between the ET10 values of the groups at 
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baseline or between the ET10 values of saline-treated mice across time.  Taken 
together, these data further support the hypothesis that 5.5 days of morphine 
treatment significantly increase thermal sensitivity during spontaneous morphine 
withdrawal.  
 
Effects of buprenorphine on thermal sensitivity during spontaneous 
morphine withdrawal. 
Buprenorphine is a partial mu-opioid receptor agonist and, like all mu-
opioid agonists, it produces antinociception on the hot plate.  Consequently, prior 
to determining whether buprenorphine would attenuate withdrawal induced 
increases in thermal sensitivity, a dose of buprenorphine that did not produce 
antinociception on its own was identified.  
Fig. 2.3a presents the dose-effect curve of buprenorphine (0.01 mg/kg-
0.32 mg/kg) at each of the temperatures used during the thermal sensitivity 
testing.  Based on these data, a dose of 0.01 mg/kg buprenorphine was selected 
since this dose did not produce measurable antinociception on the hot plate at 50, 
52, 54 or 56oC  
Fig. 2.3b shows the ET10 value at baseline, 8, 24, 32, and 48 hrs 
following termination of 5.5 days of twice daily morphine. As in Experiment I, 
ET10 values represent the theoretical temperature necessary to produce a 10 
sec response on the hot plate.  All mice in this experiment received 56 mg/kg 
morphine.  During the withdrawal period, mice received saline or 0.01 mg/kg 
buprenorphine treatment 30 min prior to test sessions at 8, 24, 32 and 48 hrs.  
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Immediately following the final morphine injection (0 hr), response latencies were 
at the cut off value of 20 sec at all temperatures; consequently these data are not 
shown. 
A 2-way repeated measures ANOVA revealed a time x group interaction 
F(4, 56) = 3.739, p<0.01, respectively.  Individual groups and time points were 
compared using appropriate follow up contrasts.  Significant differences were 
apparent between the buprenorphine-treated and saline-treated groups at 24 and 
32 hours, t56=3.94, 3.56, p<0.001, respectively.  Additionally, response latencies 
of buprenorphine-treated mice showed no difference from baseline throughout 
the withdrawal period (p>0.01). However, significant differences were again 
apparent between the saline-treated group and baseline at all withdrawal time 
points (8, 24, 32, and 48 hrs), t56=3.66, 6.35, 6.65, 3.74, p<0.001.  These data 
suggest that buprenorphine can attenuate the decrease in response latency 
observed during morphine withdrawal. 
 
Jumping behavior during spontaneous withdrawal from 30, 56, or 100 
mg/kg morphine.  
Experiment III assessed jumping responses during a 30-min period at 
baselines and at 0, 8, 24, 32, and 48 hrs following termination of the 5.5 day 
treatment period with either 30, 56, 100 mg/kg morphine or saline (s.c., twice 
daily).  Jumping responses provide a measure of withdrawal for comparison to 
the thermal sensitivity data. 
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Fig. 2.4 shows the number of jumps obtained at the morning (10:00 am) 
and evening (6:00 pm) baselines.  Jumping responses during the withdrawal 
period are presented and analyzed as jumps observed during the withdrawal 
period minus the average number of jumps that occurred during the 
corresponding baseline period (i.e., 0, 24, and 48 hrs minus AM baseline; 8 and 
36 hrs minus PM baseline). This adjustment for AM and PM baseline measures 
was included since baseline differences were observed at the two time periods. 
A 2-way repeated measures ANOVA revealed a time x group interaction 
F(12, 108) = 2.87, p<0.01, respectively.  Individual groups and time points were 
compared using appropriate follow up contrasts. Significant differences in 
adjusted jumping between mice treated with 56 mg/kg morphine and saline were 
apparent at 24, 32 and 48 hrs, t108= 5.81, 3.61, 3.66, p<0.001, respectively. A 
significant difference was seen in adjusted jumping between mice treated with 
100 mg/kg morphine and saline at 24 hrs, t108= 4.43, p<0.001.  In addition, 
immediately following the final morphine injection (0 hr), no jumping was 
observed in any of the morphine treated mice.  
Taken together, these data suggest that 5.5 days of morphine is sufficient 
to produce significant changes in jumping behavior compared to saline controls.  
However, as seen in Experiment I, the extent of this response varies with the 
dose of morphine (30, 56, or 100 mg/kg), with the greatest effects observed 
following 56 mg/kg.   
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DISCUSSION 
 
The experiments yielded three main findings. First, the results from 
Experiment I supported the hypothesis that the measurement of changes in 
thermal sensitivity provides a reliable method for assessing spontaneous 
withdrawal from morphine in mice.  Second, Experiment II demonstrated that 
buprenorphine could attenuate changes in thermal sensitivity as measured by 
latency to respond on the hot plate.  Third, the results from Experiment III 
indicated that changes in thermal sensitivity during withdrawal were similar to 
changes in jumping behavior, a well-established measure of morphine withdrawal.   
Taken together, these data validate the thermal sensitivity procedure as a 
method for assessing spontaneous morphine withdrawal.   
In the first experiment, an orderly temperature by latency relationship was 
observed at all time points, with increasing temperatures producing shorter 
response latencies.  Treatment with all three of the morphine doses (30, 56, or 
100 mg/kg) produced significant decreases in response latency on the hot plate 
following the cessation of morphine treatment.  The downward displacement of 
the temperature-response curves was most prominent at 52 and 54oC. At 56oC, 
response times were so short that changes in response time were difficult to 
detect. The response latencies of saline-treated control groups were consistent 
across all time points.  This illustrates that neither 1) repeated testing nor 2) time 
of day measurably affected responding on the hot plate.  Finally, across all 
experimental groups there was little within-group variability as measured by 
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standard error.  The observation that mice were more sensitive to a thermal 
stimulus during morphine withdrawal is consistent with previous research in both 
humans and animals reporting heightened sensitivity to thermal stimuli following 
termination of a regimen of morphine administration (Angst et al. 2003; Compton 
et al. 2003; Dunbar and Pulaj 1998; Rubovitch et al. 2009; Sweitzer et al. 2004).  
The effect of dose and the time course of withdrawal are clearly apparent 
in the ET10 data, where a single latency score was generated for each time point.   
It is well established that dose of morphine is a factor in the severity of physical 
dependence (e.g., Papaleo and Contarino, 2006).  In the experiment reported 
here, looking at the totality of the week-long withdrawal period, treatment with 56 
mg/kg morphine produced a more pronounced increase in sensitivity than 30 
mg/kg morphine; however, the time course during which the behavior was 
expressed was similar following both 30 and 56 mg/kg.  For both groups, thermal 
sensitivity peaked in the second day following the cessation of morphine 
administration and showed a return toward baseline levels by one week.   
 The magnitude of the change in ET10 value in mice treated with 100 
mg/kg morphine was similar to that of mice treated with 56 mg/kg; however, the 
time course of this decrease was shifted temporally.   We speculate that 
treatment with 100 mg/kg morphine produced a more severe withdrawal 
syndrome and that a change in thermal sensitivity was only apparent as physical 
dependence eased during the spontaneous withdrawal period.  It is possible that 
other symptoms of withdrawal such as sedation blocked the measurement of 
increases in thermal sensitivity or that this behavior is only apparent at a certain 
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magnitude of withdrawal severity.  Taken together, these data suggest that a 
change in latency to respond on the hot plate is a sensitive measure of morphine 
withdrawal; however, time, dose and hot plate temperature are all critical 
variables to consider when using this measure. 
The second experiment demonstrated that changes in thermal sensitivity 
during withdrawal could be attenuated by treatment with buprenorphine.  
Buprenorphine was selected because it is commonly used in agonist 
replacement therapy for opioid dependence (Kraus et al., 2011).  Mice received 
either saline or a non-antinociceptive dose (0.01 mg/kg) of buprenorphine during 
the withdrawal period, following the cessation of 5.5 days of 56 mg/kg morphine. 
The response latency of buprenorphine-treated mice was attenuated compared 
to saline-treated mice at 24 and 32 hrs.  Mice that received saline during the 
withdrawal period showed the same course of withdrawal as mice similarly 
treated with 56mg/kg morphine in Experiment I.   
Experiment III examined jumping behavior as a measure of withdrawal 
severity.   Jumping was selected for comparison because it is a well-established 
measure of opioid withdrawal (e.g. Saelens et al., 1971; Kest et al., 2002; and 
Papaleo and Contarino, 2006). In the current experiment, withdrawal severity, as 
measured by number of jumps in a 30-min period replicated the findings of the 
thermal sensitivity experiments.  Termination of treatment with 56 mg/kg 
morphine produced the most pronounced increase in jumping compared to 
treatment with 30 mg/kg or 100 mg/kg morphine.  Experiment III revealed two 
major limitations of using jumping to assess withdrawal severity. First, baseline 
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data indicate that time of testing (early or late in the dark-cycle) can affect 
responding.  Second, within-group variability for the jumping response is 
relatively large. As a result, it is more difficult to determine whether differences 
between experimental groups are significant when jumping is used to measure 
withdrawal.   
The most notable limitation of the thermal sensitivity procedure examined 
here is the difficulty in automating the measure since it is time intensive and 
requires observers who are well trained in the observation of hot plate responses. 
Nevertheless, the thermal sensitivity procedure could be adjusted for higher 
throughput screening by examining latencies at a single temperature (52oC) and 
a single time point (24 or 32 hrs).  Additionally, the procedure could be adapted 
for within subject (baseline v withdrawal period) or between subject (treatment 
group v untreated withdrawal group) designs.   
In summary, the present study supports the use of thermal sensitivity, as 
measured by changes in response latency on the hot plate, as a reliable method 
for assessing spontaneous morphine withdrawal in mice.   Response latencies 
on the hot plate show little variability within groups and little effect of repeated 
testing, maximizing sensitivity to subtle changes in withdrawal severity.  The 
procedure is also well suited for examining withdrawal over longer periods, a 
distinct advantage over procedures in which withdrawal is precipitated by an 
antagonist and withdrawal behaviors are observed at a single time point.  These 
characteristics make the thermal sensitivity procedure optimal for assessing the 
efficacy of medications and environmental interventions for alleviating opioid 
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withdrawal.  In fact, our laboratory recently showed that two environmental 
interventions, i.e., access to a running wheel and group housing, could attenuate 
the increase in thermal sensitivity observed during spontaneous withdrawal from 
morphine (Balter and Dykstra, 2012).   
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1 Effects of 30, 56 or 100 mg/kg morphine or saline treatment on 
latency (mean ±SEM) to respond on the hot plate at 50, 52, 54, and 56o C. 
Morphine or saline treatment consisted of 5.5 days of twice daily injections (s.c.).  
Latency on the hot plate was determined at baseline and at 8, 24, 32, 48 hrs, and 
1 wk after the final injection. Abscissa: hot plate temperature in o C. Ordinate: 
latency to respond in seconds. N=7-8.  Statistically significant differences 
(p<0.001) are indicated as follows:  A= 30 mg/kg v. sal, B= 56 mg/kg v sal, C= 
100 mg/kg v sal, X= 56 mg/kg v 30 and 100 mg/kg, Y= 100 mg/kg v 30 mg/kg. 
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 Fig. 2.2 ET10 values (mean ±SEM) for mice following 5.5 days of 30, 56 or 
100 mg/kg morphine or saline treatment.  ET10 values represent the 
temperature that would produce a 10 sec response on the hot plate. Response 
latency on the hot plate was determined at baseline and at 8, 24, 32, 48 hrs and 
1 wk after the final injection.  N=8.  Statistically significant differences are 
indicated as follows: *= a difference from the group’s baseline,  # = a difference 
between morphine and saline treated mice at a particular time point. p<0.001 
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Fig. 2.3 The effect of 0.01 mg/kg buprenorphine on withdrawal from 5.5 
days of 56 mg/kg morphine.  A. Dose-effect curves for buprenorphine (0.01- 
0.32 mg/kg) at 50, 52, 54, and 56oC. Mean latencies (±SEM ) are presented as % 
maximum possible effect (%MPE).  B. ET10 values (mean ±SEM) for mice 
treated with 0.01 mg/kg buprenorphine or saline following 5.5 days of 56 mg/kg 
morphine.  ET10 values represent the temperature that would produce a 10 sec 
response on the hot plate. Response latency on the hot plate was determined at 
baseline and at 8, 24, 32, and 48 hrs after the final morphine injection.  Mice 
received 0.01 mg/kg buprenorphine (s.c.) 30 min prior to each hot plate test 
session.  N=8.  Statistically significant differences are indicated as follows: *= a 
difference from the group’s baseline,  # = a difference between buprenorphine 
and saline treated mice. p<0.001 
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Fig. 2.4 Jumps (mean ±SEM) adjusted for baseline following 30, 56 or 100 
mg/kg morphine or saline.  Morphine or saline treatment consisted of 5.5 days 
of twice daily injections (s.c.).  Jumping was determined at baseline and at 0, 8, 
24, 32, and 48 hrs after the final injection.   Baseline jumps indicate total jumping 
in 30 min at 10am and 6pm.  Jumps at 0, 8, 24, 32, and 48 hrs indicate jumps 
observed during the 30-min withdrawal period minus the average number of 
jumps that occurred during the corresponding baseline period. Data obtained for 
the 0, 24, and 48 hrs withdrawal period fell in the AM; therefore, total jumps were 
adjusted using baseline measures from the AM period. Data obtained for the 8 
and 36 hrs withdrawal period fell in the PM; therefore, total jumps were adjusting 
using baseline measures from the PM period. N=8.  * = a statistically significant 
difference compared to saline treated mice. p<0.001
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Chapter 3 
The effect of wheel access on morphine withdrawal in C57BL/6J mice 
 
INTRODUCTION 
 
There is a growing body of literature examining the effects of voluntary 
exercise on responses to drugs of abuse.  In humans, short periods of aerobic 
exercise have been shown to reduce the desire for alcohol and tobacco (Ussher 
et al. 2004; Taylor and Katomeri 2007). Exercise also reduces symptoms of 
nicotine withdrawal and aids in smoking cessation (Taylor and Ussher 2005; 
Taylor and Katomeri 2007).  It is possible that such behavioral effects are due to 
increases in levels of endogenous opiates following aerobic exercise in the blood 
(Mahler et al. 2009; Cohen et al. 2010) as well as in the brain (Becker et al. 
2008). 
In animals, access to running wheels decreases oral self-administration of 
both amphetamine and alcohol (Kanarek et al. 1995; Hammer et al. 2010). 
Wheel running also reduces morphine self-administration and morphine 
conditioned place preference (Lett et al. 2002; Hosseini et al. 2009).  Many 
studies have shown that wheel running attenuates morphine’s antinociceptive 
43 
 
potency, suggesting that running may alter the functioning of the opiate system 
(Kanarek et al. 1998; Mathes and Kanarek 2001; Smith and Yancey 2003; Smith 
and Lyle 2006). Beyond altering acute drug effects, wheel access also reduces 
cognitive deficits and anxiety associated with spontaneous morphine withdrawal 
in rats (Miladi-Gorji et al., 2011, 2012).   
Given the evidence suggesting that exercise can alter the effects of 
opioids, the present study examines the effect of access to running wheels in the 
home cage on spontaneous morphine withdrawal in mice. Withdrawal is 
assessed following the termination of a regimen in which mice receive injections 
of either 30 or 56 mg/kg morphine (s.c.) twice-daily over a period of six days.   
Withdrawal severity is examined at multiple time points (8, 24, 32 and 48 
hrs) following the termination of morphine administration.  Unlike withdrawal that 
is precipitated by an opioid antagonist such as naloxone, spontaneous 
withdrawal takes place over an extended time period that allows mice to have 
access to running wheels throughout the withdrawal period. Additionally, 
spontaneous withdrawal, as opposed to antagonist precipitated withdrawal, more 
closely parallels the human experience.  
Since it is well-documented that the termination of a regimen of chronic 
morphine administration often results in heightened sensitivity to sensory stimuli 
(Kaplan and Fields 1991; Simonnet and Rivat 2003; Sweitzer et al. 2004), 
including painful stimuli, withdrawal severity is quantified by determining 
sensitivity to a thermal stimulus on a hot plate analgesia meter. Measures of 
thermal sensitivity have been used previously to examine morphine withdrawal in 
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both humans (Angst et al. 2003; Compton et al. 2003) and rodents (Tilson et al. 
1973; Dunbar and Pulai 1998; Crain and Shen 2007; Rubovitch et al. 2009). 
In addition, this study examined the relationship between access to a 
running wheel, attenuation of opioid withdrawal and endogenous opioid activity.  
Specifically, the effect of wheel access on opioid withdrawal was examined in the 
presence of the opioid antagonist, naltrexone.   Studies have also shown that 
naloxone, a similar opioid antagonist, can precipitate opiate-like withdrawal 
following aerobic activity and beta-endorphin administration (Kanarek et al., 
2009; Park et al., 2012). In the present experiment naltrexone, as opposed to 
naloxone, was used because it has a higher potency (Verebey and Mulé, 1975) 
as well as a lower Ki for both mu opioid receptor binding and antagonist activity 
(Wang et al., 2007).  Furthermore, naltrexone is selective for the mu and kappa 
opioid receptors as compared to the delta receptor (Wang et al., 2007). 
For this study, we hypothesize 1) that morphine- treated mice will be more 
sensitive to a thermal stimulus during withdrawal than control mice treated with 
saline, 2) that this increase in thermal sensitivity will be attenuated in mice that 
have access to running wheels and 3) that acute naltrexone administration during 
withdrawal will block the effect of wheel access. 
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METHODS 
 
Animals 
All experiments were conducted in male C57BL/6J mice (Jackson Labs, Raleigh, 
NC), 10 weeks of age upon delivery. Male C57BL/6J mice were selected to allow 
comparison with other data collected in our laboratory as well as the extensive 
behavioral literature in these mice. Additionally, in comparison to other inbred 
strains, C57BL/6J mice are known to be highly sensitive across many behavioral 
assays.  Specifically, they exhibit high sensitivity in measures of acute 
nociception (Mogil et al 1999), naloxone precipitated morphine withdrawal (Kest 
et al. 2002) and morphine self-administration (Elmer et al. 2009).  Finally, 
C57BL/6J mice are known to exhibit high rates of voluntary wheel running (Clark 
et al. 2011).  
Mice were individually housed in polycarbonate cages (floor area=335cm2) 
with continuous access to food and water throughout the study. The colony room 
was maintained on a 12-hr, reverse, light/dark cycle (lights off at 7:00 am) and all 
behavioral testing was conducted during the dark cycle, between 9:00 am and 
7:00 pm. Mice were habituated to handling and the colony room environment for 
two weeks prior to any experimental manipulation. Mice were also exposed to the 
testing environment for at least two days prior to initiation of an experiment and 
for 1 hr prior to all behavioral testing. Although a criterion was set such that mice 
<20 g or those that lost >20% of initial body weight would be removed from the 
study, it was not necessary to remove any mice from the study.  Animal protocols 
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were approved by the Institutional Animal Care and Use Committee, and the 
methods were in accord with the “Guide for the Care and Use of Laboratory 
Animals” (Institute of Laboratory Animal Research, Commission on Life Sciences, 
National Research Council, 2011). 
 
Experimental Procedures 
Experimental Groups: Mice were assigned to one of four groups during 
each of three, three-week experimental sessions (described below). New mice 
were used for each experiment.  
Experiment I: 1) morphine treatment (30 mg/kg), no wheel access; 2) 
morphine treatment (30 mg/kg), wheel access; 3) saline, no wheel access and 4) 
saline, wheel access. N=8 for morphine treated mice, n=7 for saline treated mice. 
Experiment II: 1) morphine treatment (56 mg/kg), no wheel access; 2) 
morphine treatment (56 mg/kg), wheel access; 3) saline, no wheel access and 4) 
saline, wheel access. N=8 for all groups. 
Experiment III: All mice were treated with 56 mg/kg morphine. Naltrexone 
or saline was administered 32 hrs after the final morphine injection. 1) naltrexone 
(0.01 mg/kg), no wheel access; 2) saline, no wheel access; 3) naltrexone (0.01 
mg/kg), wheel access and 4) saline, wheel access. N=8 for all groups. 
 
Wheel Access: Mice in wheel access groups had Med Associates Mouse 
Low-Profile Wireless Running Wheels in their home cages. Activity on the wheels 
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was monitored continuously (24 hr/day) via a computer equipped to record radio 
signals from the wheels. 
 
Thermal Sensitivity: Thermal sensitivity was assessed using a hot plate 
analgesia meter (25.3 × 25.3 cm), Columbus Instruments, Columbus, OH.  
During each 1-hr hot plate testing period, a temperature-effect curve was 
determined for each mouse.  Sensitivity was evaluated by recording the latency 
to lick or flutter the hind paw(s), or to jump from the hot plate surface at each of 
four temperatures presented in the following order: 50, 54, 52, 56oC with 15-min 
intervals between temperatures.  Response latency was measured to the nearest 
0.1 sec. To prevent tissue damage, a predetermined cutoff time of 20 sec was 
defined as the maximal trial duration. Immediately following the termination of a 
trial, whether due to a mouse’s response or elapsed cutoff time, mice were 
removed from the hot plate surface. Parameters were selected based on prior 
work in our laboratory regarding responses on the hot plate (e.g. Fischer et al. 
2008). 
 
Experimental Protocol: On day one, thermal sensitivity was assessed in all 
groups of mice (baseline 1).  Immediately following baseline 1, running wheels 
were placed in the cages of mice in wheel access groups.  One week later on 
day 8, a second baseline measure (baseline 2) was determined in all groups of 
mice and wheels were removed from the cages.  The average of baseline 1 and 
baseline 2 was used for data analysis and is presented in all figures.  One week 
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later on day 15, morphine or saline administration began as described below and 
continued for 5.5 days. Immediately following the final injection of morphine or 
saline (day 20), thermal sensitivity was assessed again, and wheels were 
returned to the cages of mice in the wheel access groups.  Following the last 
dose of morphine, thermal sensitivity was assessed four more times in 
Experiment I and II: at 8 hrs after the final injection (6:00 pm on day 20), at 24 hrs 
(10:00 am on day 21), at 32 hrs (6:00 pm on day 21) and at 48 hrs (10:00 am on 
day 22). In Experiment III, thermal sensitivity was assessed three more times: at 
24 hrs after the final injection (10:00 am on day 21), at 32 hrs (6:00 pm on day 
21) and at 56 hrs (6:00 pm on day 22). This period (days 20-22) was designated 
the withdrawal period. 
  
* = 1 week of wheel exposure for mice in wheel access groups 
BL= Baseline assessment of thermal sensitivity on the hot plate. WD= 8, 24, 32 
and 48hr hot plate test sessions after the final morphine injection.  
Pharmacological Procedure: During the saline/morphine administration 
period, doses of saline, 30 mg/kg or 56 mg/kg of morphine were administered 
daily for 5.5 days, with injections occurring at 10:00 am and 8:00 pm daily (11 
injections total). In Experiment III, 0.01mg/kg naltrexone was administered 
immediately prior to the 32 hr time point. 32 hrs (6:00pm) is at the end of the dark 
cycle maximizing the likelihood of wheel use prior to testing.   Morphine sulfate 
and naltrexone hydrochloride, provided by the National Institute on Drug Abuse 
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(Bethesda, MD, USA), were dissolved in 0.9% saline to yield all concentrations. 
Doses were injected subcutaneously at a volume of 0.1 ml/10 g. 
 
Data analysis 
 Data are presented as response latencies on the hot plate, expressed as 
means (+SEM) at each of the four temperatures.  For each experimental group, a 
2-way repeated measures ANOVA revealed no difference between baseline 1 
and baseline 2; therefore, baselines were averaged for all analyses.  Each 
experiment was first analyzed using a 3-way repeated measures ANOVA, with 
time and temperature as repeated measures factors and group as an 
independent factor.  For the 3-way ANOVA, an alpha level of significance was 
set at p<0.01.  Following the 3-way ANOVA, appropriate follow-up contrasts and 
Student’s t-tests were performed using a fully saturated mixed model of the data.  
The model was a straight model of the means and included random intercepts for 
each animal. Statistical analyses were conducted with an alpha level of 
significance set at p<0.001. The alpha level was determined using Bonferoni 
corrections to account for the large number of comparisons.  The ANOVA’s were 
performed using SPSS for Windows software, version 9.0.  All post hoc analysis 
was performed using SAS for Windows software, version 9.2.  Figures were 
created with GraphPad Prism 5. 
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RESULTS 
 
In general, three findings were consistent for experiments I and II.  First, 
latency to respond on the hot plate decreased as a function of temperature.  
Response latencies in both saline and morphine-treated mice were at or close to 
the maximal value of 20 sec when the hot plate was set at 50oC; at 52, 54 and 
56oC.  Latency to respond on the hot plate decreased as a function of 
temperature. Second, response latencies at the 0 (data not shown), 8, 24, 32 and 
48-hr time points for saline-treated mice were never significantly different from 
baseline, calculated as the average of baseline 1 and 2, indicating that repetition 
of testing did not produce measurable effects on response latency.  Third, 
response latencies for all groups of saline-treated mice were nearly identical at 
all time points. 
In addition, immediately following the final morphine injection (0 hr), 
response latencies were at the cut off value of 20 sec at all temperatures for 
morphine-treated mice; consequently these data are not shown.  The failure to 
respond within in the 20 sec maximal trial duration indicates a full antinociceptive 
response to acute morphine exposure. 
 
Experiment I: The effect of wheel access following 30 mg/kg morphine 
Fig. 3.1 shows latency to respond on the hot plate as a function of 
temperature at baseline, 8, 24, 32 and 48 hrs following termination of the 5.5 day 
treatment period of either 30 mg/kg morphine or saline. A 3-way repeated 
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measures ANOVA revealed a time x temperature x group interaction F(36, 312)= 
1.93, p=0.002. Follow up contrasts and Student’s t-tests were then used to 
compare individual groups, time points, and temperatures.  Although the 
temperature-effect curves revealed the same orderly relationship in all mice and 
at all time points, the curves of the mice in the morphine-treated/no wheel group 
were displaced downward from those obtained at baseline. This displacement 
was significant at 24, 32 and 48 hrs following the final morphine injection. 
F(4,494)= 11.23, 11.51, 6.53, respectively, p<0.001. 
Significant differences between the morphine-treated/no wheel mice and 
saline-treated mice were apparent at a 24 hrs (52 and 54 oC), 32 hrs (52 and 
54oC) and at 48hrs (54 oC): F(2,494)= 16.14, 10.30, 17.15, 9.36, 11.59, 
respectively, p<0.001.  These differences suggest that mice treated with 30 
mg/kg of morphine for 5.5 days and then withdrawn from morphine were more 
sensitive to the thermal stimulus than mice treated with saline at 24, 32 and 48 
hrs.  Furthermore, response latencies of mice that were treated with morphine 
and given access to running wheels during the withdrawal period were 
significantly different from those of mice that did not have access to wheels 
during the withdrawal period at 24 hrs (52 oC), 32 hrs (52 and 54 oC) and at 48hrs 
(52 oC): t494= 4.13, 3.59, 3.80, 4.13, respectively, p<0.001. 
Moreover, response latencies of morphine-treated mice with wheel access 
were similar to those of saline-treated mice at all but one point (48 hrs, 52 oC. 
F(2,494) =7.78, p<0.001). Taken together, these data suggest that wheel access 
attenuated the increase in thermal sensitivity observed during withdrawal from 30 
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mg/kg of morphine and produced response latencies similar to those seen in 
saline controls.   
 
Experiment II: The effect of wheel access following 56 mg/kg morphine 
Fig. 3.2 shows latency to respond on the hot plate as a function of 
temperature at baseline, 8, 24, 32 and 48 hrs following termination of the 5.5 day 
treatment period of either 56 mg/kg morphine or saline. A 3-way repeated 
measures ANOVA revealed a time x group interaction F(12, 112) = 4.50, p<0.001 
and a temperature x group interaction F(9, 84)=4.75, p<0.001.  Follow-up 
contrasts and Student’s t-tests were then used to compare individual groups, 
time points, and temperatures.  The temperature-effect curves again revealed an 
orderly relationship in all mice and at all time points. Additionally, the curves of 
morphine-treated/no wheel mice were again displaced downward from those 
obtained at baseline and this displacement was significant at 8, 24, 32 and 48hrs 
following the final morphine injection F(4, 532)= 6.70, 10.75, 12.60, 14.35, 
respectively, p<0.001.  
Significant differences between the morphine-treated/no wheel mice and 
saline-treated mice were apparent at 8 hrs (52 and 54 oC)  F(2,532)= 10.25, 7.12, 
p<0.001; at 24hrs (52 and 54 oC) F(2,532)=11.85, 16.82, p<0.001; at 32hrs (50, 
52, 54 oC) F(2,532)= 9.72, 21.32, 17.09, p<0.001; and at 48hrs (50, 52, 54 oC)  
F(2,532)= 6.98, 24.56, 14.30, p<0.001.  These differences suggest that mice 
treated with 56 mg/kg of morphine for 5.5 days and then withdrawn from 
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morphine were more sensitive to the thermal stimulus at 8, 24, 32 and 48 hrs 
than mice treated with saline.   
Furthermore, response latencies of mice that were treated with morphine 
and given access to running wheels during the withdrawal period were 
significantly different from those of mice that did not have access to wheels 
during the withdrawal period at 8 hrs (52 and 54 oC) t532= 3.44, 3.53, p<0.001; at 
24hrs (52 and 54 oC) t532= 4.09, 4.97, p<0.001; at 32hrs (50, 52, 54
 oC) t532= 3.75, 
4.78, 5.95, p<0.001; and at 48hrs (52 and 54 oC) t532= 4.09, 4.97, p<0.001. 
There were no significant differences in the response latencies of 
morphine-treated mice with wheel access and those of saline-treated mice. 
Taken together, these data further support the hypothesis that wheel access 
attenuated the increase in thermal sensitivity observed during withdrawal from 56 
mg/kg of morphine and produced latencies similar to those seen in saline 
controls.   
 
Experiment III: 0.01 mg/kg Naltrexone blocks the effect of wheel access 
Fig. 3.3 shows latency to respond on the hot plate as a function of 
temperature at baseline, 24, 32 and 56 hrs following termination of the 5.5 day 
treatment period of 56 mg/kg morphine. A dose of 0.01mg/kg naltrexone or saline 
was administered immediately prior to the 32 hr time point.  A 3-way repeated 
measures ANOVA revealed a time x group interaction F(9, 84)= 10.63, p<0.001, 
respectively.  Follow-up contrasts and Student’s t-tests were then used to 
compare individual groups, time points, and temperatures.  The temperature-
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effect curves again revealed an orderly relationship in all mice and at all time 
points. Prior to naltrexone treatment, at 24hrs, response latencies of mice in the 
naltrexone/wheel access group were significantly different from those of the 
naltrexone/no wheel access: at 50 and 52oC, t420= 1.75, 4.59, p<0.001. 
Significant differences were also apparent between the response latencies of 
mice in the saline/wheel access and the saline/no wheel access groups: at 52 
and 54oC, t420= 4.36, 3.42, p<0.001. There were no differences between the 
responses of the two groups that had wheel access and the two groups that did 
not have wheel access. 
At 32 hrs, a significant difference was apparent between the response 
latencies of the saline and naltrexone treated wheel access groups, F(4, 
420)=4.94, p<0.001. Latencies of the wheel access/saline group were also 
significantly different from those of the no wheel access groups at 52oC F(2, 
420)= 9.26,  p<0.001.  Additionally, there was no significant difference between 
responses of the wheel access group treated with naltrexone and those of the no 
wheel access groups: latencies at 50, 52, 54, 56oC F(2, 420)= 0.32, 0.31, 0.01, 
and 0.14, respectively, p>0.7.   
At 56 hours, response latencies of mice in the naltrexone/wheel access 
group were again significantly different from those of the naltrexone/no wheel 
access: at 52 and 54oC, t420= 5.73, 3.74, p<0.001. Significant differences were 
also apparent between the response latencies of mice in the saline/wheel access 
and the saline/no wheel access groups: at 50 and 52oC, t420= 3.76, 4.08, p<0.001. 
There were no differences between the responses of the two groups with wheel 
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access and the two groups with no wheel access.  A within subject analysis 
showed a significant difference in response latency of the naltrexone/wheel 
access group at 32 hrs as compared to both 24 and 56 hrs, F(4,420)= 14.88, 
15.67, p<0.001.  Conversely, the response latency of saline treated mice with 
wheel access was no different at 32 hrs compared to 24 or 56 hrs F(4, 420)= 
1.95, 0.82, p>0.1.  
 First, data from Experiment III replicate the effects observed in 
Experiment II, i.e., withdrawal following 56 mg/kg of morphine was attenuated in 
mice that had access to a running wheel. Secondly, access to running wheels did 
not attenuate withdrawal, as observed at 32 hrs, in mice that were pretreated 
with 0.01 naltrexone at the 32 hr time point. Importantly, naltrexone pretreatment 
alone did not alter withdrawal in mice that did not have access to a running wheel. 
When the data are compared across all three experiments, it can be seen 
that response latencies during withdrawal in morphine-treated mice without 
wheel access were consistently lower (indicating greater thermal sensitivity) than 
latencies observed during baseline conditions, as well as lower than those 
observed in saline-treated mice.  Moreover, wheel access attenuated the 
increase in thermal sensitivity, as evidenced by the fact that response latencies 
of mice with wheel access during withdrawal from both 30 and 56 mg/kg of 
morphine were very similar to those observed in saline controls. Finally, 
administration of naltrexone (0.01mg/kg) at one point during the withdrawal 
period reversed the effect of wheel access. 
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DISCUSSION 
 
The experiments conducted yielded three main findings. First, the results 
from all three experiments indicated that thermal sensitivity reliably increased 
during withdrawal following termination of a chronic regimen of morphine 
administration. These increases in thermal sensitivity were apparent for at least 
48 hrs after morphine administration was terminated. Secondly, results from both 
Experiments I (30 mg/kg morphine) and II (56 mg/kg morphine) indicated that 
increases in thermal sensitivity during withdrawal were attenuated in mice with 
access to running wheels in their home cages. Thirdly, the attenuation by wheel 
access could be blocked by a dose of naltrexone.   
The observation that mice are more sensitive to a thermal stimulus during 
morphine withdrawal is consistent with other research in both humans and 
animals reporting heightened sensitivity to thermal stimuli (Dunbar and Pulaj 
1998; Angst et al. 2003; Compton et al. 2003; Sweitzer et al. 2004; Rubovitch et 
al. 2009), including painful stimuli, following termination of a regimen of morphine 
administration.  Our findings expand on a study by Rubovich et al. (2009) 
demonstrating that thermal sensitivity also increased in a tail-flick procedure in 
mice at a single time point following termination of (or withdrawal following) 10 
days of 10 mg/kg morphine (s.c.). 
In the current experiment, both 30 and 56 mg/kg morphine given 
subcutaneously twice daily for 5.5 days produced significant decreases in 
response latency on the hot plate.  These shifts were most prominent at 52 and 
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54oC. At 56oC, response times were so short, even in control groups, that 
decreases in response time were not significant. A decrease in response latency 
(increase in thermal sensitivity) occurred within the first 24 hours after the final 
morphine injection and remained stable for at least 48 hours.  Looking at the 
totality of the 48-hour withdrawal period, treatment with 56 mg/kg morphine 
produced a more pronounced increase in sensitivity than 30 mg/kg morphine.   
This study, like others that have used similar measures of withdrawal 
(Dunbar and Pulai 1998; Rubovich et al. 2009), indicates that increases in 
thermal sensitivity can be used as a reliable measure of spontaneous opioid 
withdrawal. Although robust signs of withdrawal can also be precipitated by the 
administration of an opioid antagonist (Tilson et al. 1973; Devillers et al. 1995; 
Crain and Shen 2007), there are several advantages to a measure of withdrawal 
that occurs spontaneously (without being precipitated). First, spontaneous 
withdrawal provides a more realistic parallel to the human condition in which 
withdrawal usually does not involve precipitation with an antagonist, but rather 
involves a period in which drug is no longer available. Second, the spontaneous 
withdrawal procedure provides a method for examining treatment interventions 
that take place over time, such as wheel running or administration of long acting 
opioid agonists.  
The second important finding of the current study is the observation that 
increases in thermal sensitivity during morphine withdrawal were attenuated in 
mice that had access to running wheels in their home cages. Comparisons 
between mice that received saline and either had or did not have access to 
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wheels indicated that wheel access alone did not alter thermal sensitivity. 
However, in mice undergoing morphine withdrawal, wheel access significantly 
attenuated one very prominent sign of withdrawal, i.e., increases in thermal 
sensitivity. These findings support our hypothesis that wheel access can reduce 
withdrawal severity.  Interestingly, wheel access not only attenuated the increase 
in sensitivity observed during morphine withdrawal, but also fully returned 
thermal sensitivity to the same level observed in saline treated control mice.  
Extensive research has shown that opiate agonists, specifically 
methadone and buprenorphine are highly effective substitution treatments for 
opioid dependence (e.g. Connock et al. 2007 and Tetrault and Fiellin 2012).  In 
addition, buprenorphine has been shown to suppress spontaneous opioid 
withdrawal symptoms during the induction phase of treatment (Strain et al. 2011).   
Data from the current study indicate that access to a running wheel also 
attenuates increases in thermal sensitivity observed during withdrawal. One 
possible explanation for this finding is that wheel running leads to the release of 
endogenous opiates, thereby reducing withdrawal signs much the same way an 
opioid agonist might reduce withdrawal symptoms.  
Findings from Experiment III provide support for the hypothesis that 
attenuation of withdrawal severity in mice with wheel access is dependent on 
opioid activity.  Initially, withdrawal-induced thermal sensitivity was attenuated in 
mice that had access to a running wheel; however, this effect was blocked in 
mice that received naltrexone.  Importantly, naltrexone did not alter thermal 
sensitivity in mice that did not have access to running wheels, demonstrating that 
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naltrexone was not simply precipitating further withdrawal.  Additionally, 24 hours 
later, thermal sensitivity in mice previously treated with naltrexone was no 
different from mice treated with saline; a time course consistent with the 
metabolism of naltrexone (Verebey and Mulé, 1975). 
These data are consistent with other findings that aerobic exercise 
activates the endogenous opiate system.  Specifically, chronic wheel running in 
rats attenuates morphine’s antinociceptive potency, suggesting that cross-
tolerance develops between wheel running and morphine administration 
(Kanarek et al. 1998; Mathes & Kanarek 2001; Smith & Lyle 2006).  Additionally, 
opiate antagonists have been shown to precipitate an opioid-like withdrawal 
following chronic exercise in rats (Smith and Yancey, 2003;  Kanarek et al. 
2009).  Finally, in humans, aerobic exercise increases levels of endogenous 
opiates in the blood (Mahler et al. 2009; Cohen et al. 2010) as well as in the brain 
(Becker et al. 2008).   
The current study is primarily limited by the use of a single, behavioral 
measure of morphine withdrawal.  It will be critical to consider the effects of 
wheel access on other signs of opioid withdrawal such as jumping, wet dog 
shakes, conditioned aversion, and changes in schedule controlled responding.  
Despite limitations, the data presented here provide evidence that environmental 
manipulations such as access to running wheels can attenuate morphine 
withdrawal.  This supports the suggestion that aerobic exercise may be a 
valuable addition to interventions designed to treat drug dependence. 
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FIGURES 
 
 
Fig. 3.1 Effect of 30 mg/kg morphine or saline treatment on latency 
(mean ±SEM) to respond on the hot plate at 50, 52, 54, and 56o C. Data are 
shown for mice that had access to wheels in their home cages as well as for 
mice that did not have access to wheels.  Latency on the hot plate was 
determined at baseline and at 8, 24, 32, and 48 hrs after the final morphine 
injection. Abscissa: hot plate temperature in o C. Ordinate: latency to respond in 
seconds. Statistically significant differences are indicated as follows:  * = a 
difference between morphine- and saline-treated mice without wheel access, # = 
a difference between morphine-treated mice with and without wheel access, ^ = 
a difference between morphine-treated mice with wheel access and saline 
controls.  p<0.001 
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Fig. 3.2 Effect of 56 mg/kg morphine or saline treatment on latency 
(mean ±SEM) to respond on the hot plate at 50, 52, 54, and 56o C. Data are 
shown for mice that had access to wheels in their home cages as well as for 
mice that did not have access to wheels.  Latency on the hot plate was 
determined at baseline and at 8, 24, 32, and 48 hrs after the final morphine 
injection. Abscissa: hot plate temperature in o C. Ordinate: latency to respond in 
seconds. Statistically significant differences are indicated as follows: * = a 
difference between morphine- and saline-treated mice without wheel access, # = 
a difference between morphine-treated mice with and without wheel access. 
p<0.001 
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Fig. 3.3 Effect of 0.01mg/kg naltrexone on latency (mean ±SEM) to 
respond on the hot plate in mice with and without wheel access. All mice 
received 56 mg/kg morphine for 5.5 days. At 32 hrs following the final morphine 
injection mice received either naltrexone or saline. Data are shown for mice that 
had access to wheels in their home cages as well as for mice that did not have 
access to wheels.  Latency on the hot plate (50, 52, 54, and 56o C) was 
determined at baseline and at 24, 32, and 56 hrs after the final morphine injection. 
Abscissa: hot plate temperature in o C. Ordinate: latency to respond in seconds. 
Statistically significant differences are indicated as follows: * = a difference 
between saline-treated mice with and without wheel access, # = a difference 
between naltrexone-treated mice with and without wheel access, ^ =a difference 
between naltrexone- and saline-treated mice with wheel access. p<0.001.
  
Chapter 4 
An expanded consideration of the wheel: locked wheel, correlation, and 
group housing 
 
INTRODUCTION 
 
The results of the previous chapter demonstrate that wheel access can 
attenuate increased thermal sensitivity observed during spontaneous morphine 
withdrawal. This chapter examines further the role that wheel access plays 
during the withdrawal period.   
 There is extensive research suggesting that environmental enrichment 
can have significant effects on various behavioral assays associated with drug 
use (e.g., review by Stairs and Bardo, 2009).  Although there is no set standard 
for what constitutes an enriched environment, it often includes some combination 
of social (group housing), exploratory (toys) and exercise (running wheel) 
elements. Consequently, it is of interest to determine whether the effects of 
wheel access are dependent on wheel use (exercise) or simply the presence of a 
wheel in the cage (exploratory toy).  Although many studies on the effects of 
wheel access do not include locked-wheel controls, the majority of those that do 
conclude that the presence of a locked wheel is not sufficient to replicate the 
effects of wheel access.  For example, Pietropaolo et al., (2006) demonstrated 
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that access to unlocked but not locked wheels enhanced multiple measures of 
cognitive function.  A locked wheel also failed to produce changes seen following 
wheel running in both defensive behaviors and antidepression assays (Burghardt 
et al., 2004; Sartori et al., 2011). Additionally, access to locked wheels had no 
effect on cocaine self-administration, extinction or reinstatement (Zlebnik et al., 
2010 and 2012). Finally, the reduction of seizures during ethanol withdrawal in 
rats with wheel access did not occur in rats with locked wheel access (Devaud et 
al., 2012). 
 Although it appears that the effects of wheel access are dependent on 
wheel use, it is unclear whether the extent of wheel use is correlated with the 
strength of behavioral effects. Many studies report average running across wheel 
access groups; nevertheless, few of those studies present correlations between 
amount of running and behavioral outcomes. That said, a few studies have 
shown that the intensity of aerobic exercise is positively correlated with the 
release of beta-endorphin and other opioid peptides (Goldfarb et al., 1990; Mehl 
et al., 2000; Mougin et al., 1988). Thus, we hypothesize that there will be a 
correlation between amount of running and reduction in withdrawal severity.  This 
hypothesis is supported by findings of the Smith laboratory, which showed 
positive correlations between individual running and acute opioid sensitivity as 
well as cocaine reinforcement in rats (Smith and Lyle, 2006 and 2008). 
In addition to wheel access, the number of animals per cage is another 
variable examined in enrichment studies.  For example, single housing as 
compared to group housing of rodents alters both morphine conditioned place 
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preference as well as morphine and heroin self-administration (Alexander et al. 
1978; Bozarth et al. 1989; Bardo et al. 1997; Coudereau et al. 1997a; Raz and 
Berger 2010; Kennedy 2012). Coudereau et al. (1997b) and Broseta et al. (2005) 
both found that social isolation decreased symptoms of antagonist-precipitated 
opioid withdrawal.   
Given observations suggesting that both wheel access and housing 
conditions can alter the effects of opioids, the present study examines the effect 
of 1) a locked wheel and 2) group versus single housing on spontaneous 
morphine withdrawal in mice. The correlation between wheel use and thermal 
sensitivity is also examined.  As in previous experiments, withdrawal is assessed 
following the termination of a drug regimen in which mice receive twice-daily 
injections of 56 mg/kg morphine (s.c.) for 5.5 days.  Withdrawal severity is 
examined at multiple time points (8, 24, 32 and 48 hrs) following the termination 
of morphine administration.  Withdrawal severity is quantified by determining 
sensitivity to a thermal stimulus on a hot plate analgesia meter as described in 
previous chapters. The use of a spontaneous withdrawal procedure allows mice 
to have access to running wheels throughout the withdrawal period.   
Based on data from previous studies in our laboratory and others, we 
hypothesize that increases in thermal sensitivity observed during withdrawal will 
be attenuated in mice that have access to running wheels.  However, sensitivity 
will not be changed in mice with access to a locked wheel.  We also propose to 
examine the effects of group housing on thermal sensitivity during spontaneous 
withdrawal.   
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METHODS 
 
Animals 
All experiments were conducted in male C57BL/6J mice (Jackson Labs, 
Raleigh, NC), 10 weeks of age upon delivery. Male C57BL/6J mice were 
selected to allow comparison with other data collected in our laboratory as well 
as the extensive behavioral literature in these mice. Additionally, in comparison 
to other inbred strains, C57BL/6J mice are known to be highly sensitive across 
many behavioral assays.  Specifically, they exhibit high sensitivity in measures of 
acute nociception (Mogil et al 1999), naloxone-precipitated morphine withdrawal 
(Kest et al. 2002) and morphine self-administration (Elmer et al. 2009).  Finally, 
C57BL/6J mice are known to exhibit high rates of voluntary wheel running (Clark 
et al. 2011).  
Mice were either singly-housed (Experiment I) or group-housed, four per cage 
(Experiment II) in polycarbonate cages (floor area=335cm2) with continuous 
access to food and water throughout the study. The colony room was maintained 
on a 12-hr, reverse, light/dark cycle (lights off at 7:00 am) and all behavioral 
testing was conducted during the dark cycle, between 9:00 am and 7:00 pm. 
Mice were habituated to handling and the colony room environment for two 
weeks prior to any experimental manipulation. Mice were also exposed to the 
testing environment for at least two days prior to initiation of an experiment and 
for 1 hr prior to all behavioral testing. Criterion was set such that mice <20 g or 
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those that lost >20% of initial body weight would be removed from the study.  
Animal protocols were approved by the Institutional Animal Care and Use 
Committee, and the methods were in accord with the “Guide for the Care and 
Use of Laboratory Animals” (Institute of Laboratory Animal Research, 
Commission on Life Sciences, National Research Council, 2011). 
 
Experimental Procedures 
Pharmacological Procedure: During the saline/morphine administration 
period, doses of saline or 56 mg/kg of morphine were administered daily for 5.5 
days, with injections occurring at 10:00 am and 8:00 pm daily (11 injections total). 
Morphine sulfate, provided by the National Institute on Drug Abuse (Bethesda, 
MD, USA), was dissolved in 0.9% saline to yield all concentrations. Doses were 
injected subcutaneously at a volume of 0.1 ml/10 g. 
 
Experimental Groups: Mice were assigned to one of four groups during 
each three-week experimental session (described below). Morphine treated mice 
received 56mg/kg morphine. New mice were used for each experiment.  
Experiment I, Locked Wheel: 1) wheel access, morphine treatment; 2) 
locked-wheel access, morphine treatment; 3) no wheel access, morphine 
treatment and 4) locked wheel access, saline. N=7 for locked wheel, morphine 
treatment group, n=8 for all other groups. 
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Experiment II, Group Housing: 1) singly-housed, morphine; 2) group-
housed, morphine; 3) singly-housed, saline and 4) group-housed, saline. N=8 for 
singly-housed mice, n=7 for group-housed mice. 
 
Wheel Access: Mice in wheel access groups had Med Associates Mouse 
Low-Profile Wireless Running Wheels in their home cages. Wheels were locked 
with a small metal peg connecting the wheel and the base. Activity on the wheels 
was monitored continuously (24 hr/day) via a computer equipped to record radio 
signals from the wheels. 
 
Thermal Sensitivity: Thermal sensitivity was assessed using a hot plate 
analgesia meter (25.3 × 25.3 cm), Columbus Instruments, Columbus, OH.  
During each 1-hr hot plate testing period, a temperature-effect curve was 
determined for each mouse.  Sensitivity was evaluated by recording the latency 
to lick or flutter the hind paw(s), or to jump from the hot plate surface at each of 
four temperatures presented in the following order: 50, 54, 52, 56oC with 15-min 
intervals between temperatures.  Response latency was measured to the nearest 
0.1 sec. To prevent tissue damage, a predetermined cutoff time of 20 sec was 
defined as the maximal trial duration. Immediately following the termination of a 
trial, whether due to a mouse’s response or elapsed cutoff time, mice were 
removed from the hot plate surface. Parameters were selected based on prior 
work in our laboratory regarding responses on the hot plate (e.g. Fischer et al. 
2008). 
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Experimental Protocol: On day one, thermal sensitivity was assessed in all 
groups of mice (baseline 1).  Immediately following baseline 1, running wheels 
were placed in the cages of mice in wheel access groups.  One week later on 
day 8, a second baseline measure (baseline 2) was determined in all groups of 
mice and wheels were removed from the cages.  The average of baseline 1 and 
baseline 2 was used for data analysis and is presented in all figures.  One week 
later on day 15, morphine or saline administration began as described below and 
continued for 5.5 days. Immediately following the final injection of morphine or 
saline (day 20), thermal sensitivity was assessed again, and wheels were 
returned to the cages of mice in the wheel access groups.  Following the last 
dose of morphine, thermal sensitivity was assessed four more times: at 8 hrs 
after the final injection (6:00 pm on day 20), at 24 hrs (10:00 am on day 21), at 32 
hrs (6:00 pm on day 21) and at 48 hrs (10:00 am on day 22). This period (days 
20-22) was designated the withdrawal period.  
 
 
* = 1 week of wheel exposure for mice in wheel access groups 
BL= Baseline assessment of thermal sensitivity on the hot plate.  
WD= 8, 24, 32 and 48hr hot plate test sessions after the final morphine injection.  
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Data analysis 
ANOVA and correlation analysis was performed using SPSS for Windows 
software, version 9.0.  All post hoc analysis was performed using SAS for 
Windows software, version 9.2.  Figures were created with GraphPad Prism 5. 
 
Thermal sensitivity: Data are presented as response latencies on the hot 
plate, expressed as means (+SEM) at each of the four temperatures.  For each 
experimental group, a 2-way repeated measures ANOVA revealed no difference 
between baseline 1 and baseline 2; therefore, baselines were averaged for all 
analyses.  Each experiment was first analyzed using a 3-way repeated measures 
ANOVA with time and temperature as repeated measures factors and group as 
an independent factor.  For the 3-way ANOVA, an alpha level of significance was 
set at p<0.01.  Following the 3-way ANOVA, appropriate follow-up contrasts and 
Student’s t-tests were performed using a fully saturated mixed model of the data.  
The model was a straight model of the means and included random intercepts for 
each animal. Statistical analyses were conducted with an alpha level of 
significance set at p<0.001. The alpha level was determined using Bonferoni 
corrections to account for the large number of comparisons.   
 
Correlations: A Pearson product-moment correlation was used to compare 
individual running (simple or % of baseline) with ET10 values. The alpha level for 
correlation coefficients was set at p < 0.05. 
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Running data: During the withdrawal period running was defined as the 
total number of wheel revolutions in the seven-hour period prior to each test 
session.  This included the full inter-session interval for the 8 and 32 hr time 
points (period from 10:00 am until 5:00 pm when mice were taken into the testing 
room).  For the 24 and 48 hr time points, revolutions during the seven-hour 
period from 2:00 am- 9:00 am were used.  Baseline running was calculated using 
the average revolutions during the last two full days of the wheel pre-exposure 
period.  Separate morning (2:00 am- 9:00 am) and afternoon (10:00 am until 5:00 
pm) baselines were calculated.  Running data are presented as either simple 
revolutions or revolutions as a percent of appropriate baseline (8 and 32 hr time 
points as percent of afternoon baseline, 24 and 48 hr time points as percent of 
morning baseline). 
ET10: The ET10 represents the theoretical temperature required to 
produce a response latency of 10 sec (half the maximal response latency of 20 
sec) and was derived using log-linear interpolation. Larger ET10 values indicate 
longer response latencies and lower thermal sensitivity.   
 
RESULTS 
 
In general, two findings were consistent for both experiments.  First, 
latency to respond on the hot plate decreased as a function of temperature.  
Response latencies in both saline and morphine-treated mice were at or close to 
the maximal value of 20 sec when the hot plate was set at 50oC; at 52, 54 and 
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56oC, latency to respond on the hot plate decreased as a function of temperature. 
Second, response latencies at the 8, 24, 32 and 48-hr time points for saline-
treated mice were never significantly different from baseline, calculated as the 
average of baseline 1 and 2, indicating that repetition of testing did not produce 
measurable effects on response latency. 
In addition, immediately following the final morphine injection (0 hr), 
response latencies were at the cut off value of 20 sec at all temperatures for 
morphine-treated mice; consequently these data are not shown.  The failure to 
respond within in the 20 sec maximal trial duration indicates a full antinociceptive 
response to acute morphine exposure. 
 
Experiment I, Part I: The effect of a locked wheel following 56 mg/kg morphine 
Fig. 4.1 shows latency to respond on the hot plate as a function of 
temperature at 8, 24, 32 and 48 hrs following termination of the 5.5 day treatment 
period of either 56 mg/kg morphine or saline. A 3-way repeated measures 
ANOVA revealed time x temperature x group interaction, F(36, 324) = 1.51, 
p=0.035. Main effects of time and temperature were F(4, 108) = 60.62, p<0.001 
and F(3, 81)= 2932.32, p<0.001, respectively.  Follow-up contrasts and Student’s 
t-tests were then used to compare individual groups, time points, and 
temperatures.   
At 8, 24, 32, and 48 hrs following the final morphine injection, the curves 
of morphine-treated mice without wheel access were displaced downward from 
those of saline treated mice, F(4, 513) = 5.73, 27.96, 21.46, 23.16,  respectively, 
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p<0.001.  Additionally the response curves of morphine-treated mice with wheel 
access were no different from those of the saline-treated mice (p>0.1).   These 
data replicate the findings of the previous chapter: thermal sensitivity is increased 
during withdrawal form 56 mg/kg of morphine and attenuated by wheel access.   
The response curves of mice with a locked wheel were never significantly 
different from the curves of mice with no wheel access (p>0.1). Furthermore, 
significant differences between the response latencies morphine-treated mice 
with a locked wheel and those with an unlocked wheel were apparent at 8 hrs (52, 
54oC) t513= 3.30, 3.88; 24 hrs (50, 52
oC) t513 = 4.02, 5.73; 32 hrs (50, 52, 54
oC) 
t513  = 4.71, 7.20, 4.82; and 48 hrs (50, 52, 54
oC)t513 = 5.61, 6.95, 4.72, p<0.001.  
These differences suggest that the thermal sensitivity of mice with access to a 
locked wheel is increased during withdrawal similarly to that of mice with no 
wheel rather than attenuated like that of mice with an unlocked wheel.   
 
Experiment I, Part II: Comparison between wheel use and thermal sensitivity  
  In addition to between-group comparisons, correlations between wheel 
running and thermal sensitivity were also examined.  Fig. 4.2 shows average 
wheel revolutions during seven-hour periods throughout the experiment in the 
light and dark cycles.  A seven-hour period was selected because it included the 
entire interval from 11:00am to 5:00pm (dark period) between behavioral testing 
sessions during the withdrawal period.  To maintain consistency, seven-hour 
periods were sampled for the time prior to morning testing: 2:00 am to 9:00 am 
(light period).  During the dark cycle in the baseline, pre-morphine period, mice 
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ran an average of 9388.8 rev/ 7hrs (3.57 km / 7hrs).  Consistent with the 
nocturnal nature of mice, wheel use during the light cycle was substantially less.  
Though wheel use during the withdrawal period was greatly reduced, mice did 
use the wheels during this period.   
Fig. 4.3 shows the correlation between individual wheel use and hot plate 
response during the withdrawal period.  All panels present hot plate response as 
an ET10 value derived from the latency data shown in Fig. 4.1.  ET10 values 
represent the theoretical temperature necessary to produce a 10 sec response 
on the hot plate.  Thus, higher ET10 values indicate longer response times and 
lower thermal sensitivity.  In panels A-D, individual running data are presented as 
revolutions during the prior seven-hour period.  In panels E-H, running data are 
presented as a percent change in revolutions from matched baseline (light or 
dark cycle). Correlation coefficients failed to reach statistical significance 
(p<0.05).  For correlations with p<0.1, r values were as follows: 8hrs (%BL),         
r = -0.71; 32 hrs (total revs), r = -0.66; 32 hrs (%BL), r = -0.66; 48hrs (total revs), 
r = 0.67; 48hrs (%BL), r = 0.70.   These data suggest a trend towards a negative 
correlation between wheel use and thermal sensitivity at 32 hrs and a positive 
correlation at 48 hrs.  
 
Experiment II: 56 mg/kg Morphine, Group Housing 
In Experiment II mice were either housed in groups of 4 or singly housed. 
Fig. 4.4 shows latency to respond on the hot plate as a function of temperature at 
baseline, 8, 24, 32 and 48 hrs following termination of the 5.5 day treatment 
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period of either 56 mg/kg morphine or saline.   A 3-way repeated measures 
ANOVA revealed a time x temperature x group interaction, F(36, 312)=1.88, 
p=0.003. Follow-up contrasts and Student’s t-tests were then used to compare 
individual groups, time points, and temperatures.   
In comparison to baseline, the temperature-effect curves revealed the 
same orderly relationships seen previously.  The curves of the morphine-
treated/singly-housed mice showed significant differences from baseline at 8, 24, 
32, 48 hrs, respectively F(4,494)= 7.15, 23.18, 23.04, 18.80, p<0.001. In contrast, 
response latencies of morphine-treated mice that were group-housed were only 
different from baseline at 48 hrs. F(4,494)= 5.59, p=0.0002.   
Throughout the withdrawal period, differences between the response 
latencies of morphine-treated/singly-housed mice and saline-treated mice were 
apparent at 8 hrs (54 oC) F(2,494)= 7.72, p<0.001; 24 hrs (50, 52, 54 oC) 
F(2,494)= 10.40, 16.24, 14.77, p<0.001; 32 hrs (50, 52, 54 oC) F(2,494)= 9.06, 
28.58, 8.90, p<0.001; 48 hrs (52 and 54oC) F(2,494)= 23.46, 14.67, p<0.001.  
These data replicate the data obtained in the 56 mg/kg morphine-treated/ no 
wheel access groups from Experiment I.  That is, morphine-treated mice were 
more sensitive to the thermal stimulus than saline controls at 24, 32, and 48 hrs 
following termination of morphine administration.  
The response latencies of morphine-treated, group-housed mice were 
similar to those observed in the saline controls, except at three points (32 hrs, 52 
oC and 48 hrs, 52 and 54 oC).  F(2, 494)= 9.85, 11.73, 11.58, respectively, 
p>0.001. Although there was some evidence that the decrease in response 
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latencies observed in morphine-treated/singly-housed mice was attenuated in 
group-housed mice (54 oC at 8, 24 hrs t494 =5.90, 3.54, p<0.001), this attenuation 
was not as robust as that observed in Experiment I, as the result of wheel access.   
Taken together, these data replicate previous findings that 1) thermal 
sensitivity is increased during withdrawal in morphine-treated mice singly housed 
without wheel access and 2) this increase in sensitivity is attenuated with wheel 
access.  In addition, these data suggest that withdrawal is not attenuated when 
access to the wheel is locked; however, attenuation of withdrawal is not 
correlated with the amount of wheel use.  Although group housing also 
attenuated the increase in thermal sensitivity observed during withdrawal from 56 
mg/kg morphine, the attenuation was not as robust as that observed as the result 
of wheel access.  
 
DISSCUSION 
 
The experiments conducted yielded three main findings. First, the 
presence of a locked wheel in the home cage is not sufficient to alter the severity 
of morphine withdrawal, as measured by thermal sensitivity. Second, although 
thermal sensitivity during withdrawal was generally lower in mice with wheel 
access, individual thermal sensitivity was not correlated with the amount of wheel 
running. Third, an alternative form of enrichment, group housing, produced 
moderate decreases in withdrawal severity. In addition, the experiments 
replicated two important findings.   First, the results from both experiments 
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indicated that thermal sensitivity reliably increased during withdrawal following 
termination of a chronic regimen of morphine administration. Second, increases 
in thermal sensitivity during withdrawal were attenuated in mice with access to 
running wheels in their home cages.   
In the current experiment, thermal sensitivity of mice without wheels was 
significantly decreased following the termination of chronic morphine.  The 
sensitivity of mice with locked wheels was the same as that of mice without 
wheels and was significantly higher than the sensitivity of mice with unlocked 
wheels.  The observation that access to a locked wheel did not produce the 
same behavioral effects as access to an unlocked wheel is consistent with the 
majority of published findings (e.g. Burghardt et al., 2004; Devaud et al., 2012; 
Pietropaolo et al., 2006; Sartori et al., 2011; Zlebnik et al., 2010 and 2012).  
These data suggest that the effect of wheel access is dependent on wheel use 
not simply the presence of the wheel acting as a toy to explore. 
We hypothesized that mice that ran more would exhibit greater benefits 
(i.e. less thermal sensitivity during withdrawal) than mice that ran less.  The data 
of experiment 1 did not support this hypothesis.  Throughout the withdrawal 
period wheel revolutions in the hours prior to behavioral testing were not 
correlated with individual thermal sensitivity, as quantified by ET10.   ET10 
values also were not correlated with running adjusted for possible individual 
difference (revolutions as % baseline).  The initial hypothesis is based on the 
assumption that wheel revolutions are an accurate measure of aerobic exercise. 
It is possible that expended effort was correlated with withdrawal severity but was 
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masked by variation in wheel tension such that different amounts of running 
produced similar aerobic effects.  Alternatively, reduction in thermal sensitivity 
may simply require that a certain threshold of wheel use be exceeded.  Wheel 
running beyond that point will provide no further effect.  Considering the little 
variation in ET10 values between mice and the full recovery to baseline 
sensitivity, this may be a reasonable hypothesis.  Finally, the lack of correlation 
does not diminish the significant effects of wheel access during spontaneous 
withdrawal. 
Since wheel access is often placed under the umbrella of environmental 
enrichment, Experiment II examined the effect of a second environmental 
manipulation, group housing.  Comparisons between mice that received saline 
and either were singly housed or group-housed indicated that group housing 
alone did not alter thermal sensitivity. However, in mice undergoing morphine 
withdrawal, group housing attenuated the withdrawal-induced increases in 
thermal sensitivity for at least two of the time points during the withdrawal period 
(i.e., 8 and 24 hrs, but not 32 and 48 hrs). Therefore, both wheel access and 
group housing attenuated the increases in thermal sensitivity observed during 
morphine withdrawal.   
A comparison between the results from Experiment I and Experiment II 
suggests that the attenuation of thermal sensitivity during withdrawal was greater 
in mice that had access to wheels, than those that were group-housed.  
Specifically, with wheel access, significant attenuation was observed at 8, 24, 32 
79 
 
and 48 hours following the final morphine injection. Group-housed mice only 
showed clear attenuation during the earlier withdrawal period, at 8 and 24 hours.  
The finding that one symptom of withdrawal, i.e., thermal sensitivity was 
attenuated in group-housed mice is in contrast to the findings of Coudereau et al. 
(1997b) and Broseta et al. (2005), which suggested that social isolation (single 
housing) decreased the symptoms of opioid withdrawal. There are a number of 
significant methodological differences between the Coudereau and Broseta 
studies and the current study. Perhaps most importantly, the Coudereau and 
Broseta studies both examined naloxone precipitated withdrawal rather than 
spontaneous withdrawal.  Additionally, Broseta et al. (2005) only quantified 
physical symptoms of withdrawal after repeated naloxone exposure during 
conditioned place aversion.   Coudereau et al. (1997b) used younger mice (5 as 
opposed to 12 weeks old) and housed them 6, rather than 4, per cage. 
Interestingly, in studies from Burghardt et al. (2004) and Pietropaolo et al. (2006) 
that considered the effect of group housing and wheel access on cogntion and 
anxiety, group housing produced an intermediate effect between locked and 
unlocked wheel access, similar to what was observed here.  
To fully characterize the effects of group housing on morphine withdrawal, 
it is clear that additional studies examining a range of parameters (length of 
isolation/group housing, number of animals per cage, drug treatment of group-
housed peers) would be needed.  The current study is also limited by the use of 
a single, behavioral measure of morphine withdrawal.  It will be critical to 
consider the effects of group housing as well as wheel access on additional signs 
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of physical withdrawal such as jumping, wet dog shakes, conditioned aversion, 
and changes in schedule controlled responding.  It is possible that wheel running 
may correlate with individual changes in one of these other behavioral measures 
of withdrawal. Taken together, these experiments suggest that although 
environmental manipulations such as group housing may affect withdrawal 
severity, voluntary access to (unlocked) running wheel produces the most 
dramatic behavioral effect.  
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FIGURES 
 
 
 
Fig. 4.1 Effects of a locked, compared to unlocked, wheel on latency 
(mean ±SEM) to respond on the hot plate at 50, 52, 54, and 56o C in saline- 
and morphine- (56 mg/kg) treated mice.  Data are shown for mice that had 
access to locked as well as unlocked wheels.  Latency on the hot plate was 
determined at baseline and at 8, 24, 32, and 48 hrs after the final morphine 
injection. Abscissa: hot plate temperature in o C. Ordinate: latency to respond in 
seconds. *= statistically significant difference between morphine treated mice 
with access to locked as compared to unlocked wheels.  p<0.001 
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Fig. 4.2 Total revolutions (mean ±SEM) during 7hr sample periods.  
Dark cycle sample period= 10:00 am until 5:00 pm, light cycle sample period= 
2:00 am- 9:00 am. 
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Fig. 4.3 Correlation between running and response latency as 
quantified by ET10 during spontaneous withdrawal from 56 mg/k morphine.  
ET10 values represent the temperature that would produce a 10 sec response on 
the hot plate; larger values represent lower sensitivity.  Individual wheel use is 
presented as total revolutions in the prior 7hr period (A-D) or revolutions as a 
percent of individual baseline (E-H).  Data are presented with linear regression 
line 
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Fig. 4.4 Effects of group housing (4/cage) on latency (mean ±SEM) to 
respond on the hot plate at 50, 52, 54, and 56o C in saline- and morphine- 
(56 mg/kg) treated mice.  Data are shown for mice that were group-housed as 
well as for mice that were singly-housed.  Latency on the hot plate was 
determined at baseline and at 8, 24, 32, and 48 hrs after the final morphine 
injection. Abscissa: hot plate temperature in o C. Ordinate: latency to respond in 
seconds. Statistically significant differences are indicated as follows:  * = a 
difference between singly-housed mice treated with morphine and saline controls, 
# = a difference between group- and singly-housed mice treated with morphine, ^ 
= a difference between group-housed mice treated with morphine and saline 
controls.  p<0.001
  
Chapter 5 
Chronic wheel access can decrease morphine sensitivity and alter gene 
expression. 
 
INTRODUCTION 
 
Chronic administration of morphine and other opioids leads to the 
development of tolerance and physical dependence in both primates and rodents 
(e.g. Bhargava, 1978; Christie, 2008; Fernandes et al., 1977; Kamei et al., 1973; 
Sell et al., 2005).  Furthermore, once tolerance to one opioid is established 
cross-tolerance to other opioids develops as well (e.g. Dumas et al., 2008; Eyler, 
2013).  The ability of two drugs to produce “cross-tolerance” suggests similar 
sites of cellular action.   
Interestingly, multiple groups have found that chronic wheel access in rats 
can decrease morphine’s potency similarly to decreases produced by chronic 
morphine (Kanarek et al. 1998; Mathes and Kanarek 2001, 2006; Smith and 
Yancey 2003; Smith and Lyle 2006).  The fact that chronic wheel running also 
decreases morphine’s antinociceptive potency is consistent with the hypothesis 
that wheel running activates the opioid system. This is further supported by data 
reviewed by Koltyn (2000), which describes a number of studies in both humans 
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and animals showing that aerobic exercise can produce analgesic effects across 
a number of pain assays.  
The current experiment confirms the finding that extended wheel access 
decreases morphine potency.  Specifically, we hypothesize that 6 weeks of 
access to a running wheel will produce a rightward shift in the morphine dose-
effect curve as assessed by tail-flick latency. Changes in morphine’s 
antinociceptive effects are used to assess tolerance as these effects are easily 
observable, dose-dependent and reliable (Fischer et al., 2005; 2008).   
Tolerance to the antinociceptive effects of opioids is almost certainly 
concurrent with, if not caused by, various cellular changes resulting from chronic 
opioid receptor activity.  Opponent process theory provides a heuristic model 
suggesting that the changes during tolerance are the opposite of the changes 
following acute drug exposure.  As proposed, these “opposite” changes produce 
an allostatic state to balance the effects of the exogenous input.  A great deal of 
experimental literature is devoted to identifying the cellular changes that occur 
during opioid tolerance.  One subset of this body of literature considers changes 
in the expression of various genes.   
Based on these observations, the following argument might hold: if chronic 
wheel access and chronic morphine administration produce similar behavioral 
changes, then it is possible that both produce similar changes in gene expression.  
The experiments described here use quantitative real time polymerase chain 
reaction (qRT-PCR) to compare gene expression following chronic wheel access 
and chronic morphine administration.  The expression of five genes was 
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assessed: PENK, PDYN, POMC, MOR1, and BARR2.  Proenkephalin (PENK), 
prodynorphin (PDYN), and proopiomelanocortin (POMC) were selected because 
they code for the precursor proteins that are post-translationally modified into the 
three major endogenous opioids: enkephalin, dynorphin, and beta-endorphin, 
respectively, (Aghajanian and Sanders-Bush 2002). The MOR1 gene codes for 
the mu-opioid receptor (Ammon-Treiber et al 2005). Beta-arrestin 2 (BARR2) is a 
protein which regulates mu-opioid receptor desensitization and internalization 
and plays a role in the onset of opioid tolerance (Bohn et al., 2004). 
The mRNA level of each of these genes was assessed in four brain 
regions integral to the formation and expression of morphine tolerance: the 
striatum, nucleus accumbens, hypothalamus and periaqueductal grey. 
Furthermore, research has shown that chronic morphine can alter gene 
expression in each region: the striatum (Martin-Soelch et al., 2001; Gieryk et al., 
2010), the nucleus accumbens (Leriche et al., 2007; Gieryk et al., 2010), the 
hypothalamus (Wang et al., 2011; Wei et al., 2009) and the periaqueductal grey 
(Fan et al. 2003; Folkesson et al.,1989; Maldonado et al.,1992; Stamford 1995; 
Wang et al., 2011). 
 
METHODS 
 
Animals 
All experiments were conducted in male C57BL/6J mice (Jackson Labs, 
Raleigh, NC), 10 weeks of age upon delivery. Male C57BL/6J mice were 
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selected to allow comparison with other data collected in our laboratory regarding 
morphine’s pharmacological effects as well as the extensive literature on the 
behavioral effects of opioids in C57BL/6 mice. Additionally, in comparison to 
other inbred strains, C57BL/6J mice are known to be highly sensitive across 
many behavioral assays.  Specifically, they exhibit high sensitivity in measures of 
acute nociception (Mogil et al., 2000), naloxone precipitated morphine withdrawal 
(Kest et al. 2002) and morphine self-administration (Elmer et al. 2009).  
Mice were individually housed in polycarbonate cages (floor area= 335cm2) 
with continuous access to food and water throughout the study. The colony room 
was maintained on a 12-hr, reverse, light/dark cycle (lights off at 7:00 am) and all 
behavioral testing was conducted during the dark cycle, between 9:00 am and 
7:00 pm. Mice were habituated to handling and the colony room environment for 
two weeks prior to any experimental manipulation. Mice were also exposed to the 
testing environment for four days prior to initiation of the experiment and for 1 hr 
prior to all behavioral testing. Although a criterion was set such that mice <20 g 
or those that lost >20% of initial body weight would be removed from the study, it 
was not necessary to remove any mice from the study.  Animal protocols were 
approved by the Institutional Animal Care and Use Committee, and the methods 
were in accord with the “Guide for the Care and Use of Laboratory Animals” 
(Institute of Laboratory Animal Research, Commission on Life Sciences, National 
Research Council, 2011). 
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Experimental Procedures 
Experimental Groups: Mice were assigned to one of three groups: wheel 
access (n=8), no wheel access (n=8), chronic morphine (n=7).  
Mice in the wheel access group had access to Med Associates Mouse 
Low-Profile Wireless Running Wheels in their home cages for the six week 
period between determination of the first and second morphine dose-effect 
curves.  Activity on the wheels was monitored continuously via a computer 
equipped to record radio signals from the wheels.  
   
  Experimental design: Following four days of training to acclimate the mice 
to the tail-flick procedure, morphine antinociception was assessed (“pre” time 
point).  Immediately following the test session, running wheels were placed in the 
cages of mice in wheel access groups.  Six weeks later a second morphine dose-
effect curve was determined (“post” time point).  Mice in the chronic morphine 
group received morphine injections for the final 5 days of the sixth week. During 
the last four days of the sixth week, mice were again acclimated to the tail-flick 
procedure.  Immediately following the “post” dose-effect curve, the mice were 
decapitated and their brains were removed to examine gene expression.  
 
Behavioral procedures 
Tail-flick procedure: Mice were lightly restrained by hand and the animal’s 
tail was positioned over a light source. The latency to remove (i.e. flick) the tail 
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was measured twice: when the light source was positioned 5 cm and 3 cm from 
the tip of the tail. The light was immediately removed from the tail when the mice 
exhibit a response or reached the predetermined cut off point of 10 sec. 
A full dose-response curve was determined by measuring response 
latency at baseline and following 0.32, 1.0, 3.2, 10.0 and 32.0 mg/kg doses of 
morphine.  A within subject, cumulative dosing procedure, with 30 min between 
doses, was used, according to an experimental protocol that has been used 
successfully in our laboratory to investigate morphine’s antinociceptive effects.  
 
Pharmacological Procedure: For mice in the chronic morphine group, 
doses of 56 mg/kg of morphine were administered daily for 5.5 days, with 
injections occurring at 10:00 am and 8:00 pm daily (11 injections total). Morphine 
sulfate was provided by the National Institute on Drug Abuse (Bethesda, MD, 
USA), was dissolved in 0.9% saline to yield all concentrations. Doses were 
injected subcutaneously at a volume of 0.1 ml /10 g. 
 
Analysis of Tail-Flick Dose-Effect Curves: Data are presented as a 
percentage of the maximum possible effect (%MPE), expressed as means 
(+SEM) at each dose. Percentage of the maximum possible effect was calculated 
using the following formula:  
                [Postdrug latency - baseline latency] 
%MPE= ---------------------------------------------------- 
               [cutoff time (20sec) - baseline latency] 
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 For each dose-effect determination, the dose of morphine (mg/kg) 
required to produce a 50% maximal antinociceptive effect (ED50) was derived 
mathematically (least-squares method) using log-linear interpolation, with at least 
three doses on the ascending limb of the dose-effect curve. Potency ratios 
(±95% confidence limits) were calculated using a procedure from Tallarida and 
Murray (1987), and were used for comparison of ED50 values. 
 
Gene expression procedures 
Tissue collection: Immediately following determination of the second dose-
effect curve, mice were decapitated.  Decapitation without anesthesia was 
necessary because anesthesia has been shown to alter RNA transcription 
patterns (Palotas et al., 2005; Quinones-Jenab et al., 1996). The brains were 
quickly removed from the skull, the hemispheres were separated and placed in 
RNAlater (an RNAse inhibitor) and stored at -80oC.  
Subsequently, brain hemispheres were removed from the freezer and the 
striatum, nucleus accumbens, hypothalamus and periaqueductal grey were 
dissected out. See Fig. 5.1 for details of dissection. 
 
qRT-PCR procedure: Immediately following dissections, RNA was isolated 
from the tissue samples using the Qiagen RNeasy Lipid Tissue Mini Kit and 
quantified using the NanoDrop® ND-1000 Spectrophotometer.  Sodium Acetate 
precipitation was used to reduce salt contamination.  The RNA was reverse 
transcribed to cDNA using an Invitrogen SuperScript III First-Strand Synthesis 
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Super Mix Kit and run in a MJ Research PTC-225 Peltier Thermal Cycler.  
Quantitative PCR was then done to provide a measure of differential gene 
expression between samples.  For the qPCR procedure, TaqMan® primers for 
one of the five genes of interest plus the TaqMan® Gene Expression Master Mix 
were added to the cDNA samples and run in an Applied Biosystems 7300 Real 
Time PCR.  GAPDH was used as the reference gene. All samples were run in 
triplicate and threshold cycle values were averaged for calculations. 
 
Primers:  
TaqMan® primers for 5 genes were used:  proenkephalin (PENK), 
prodynorphin (PDYN), proopiomelanocortin (POMC), mu-opioid Receptor 1 
(MOR1), and beta-arrestin 2 (ARRB2).  In addition to sense and antisense 
primers for the genes of interest, primers for the reference gene GAPDH was 
used.  
TaqMan® Gene Expression  Primers: 
#Mm01212875_m1     (PENK) 
# Mm00457573_m1    (PDYN) 
# Mm00435874_m1    (POMC) 
#Mm01188089_m1     (MOR1) 
#Mm00520665_m1     (ArrB2) 
#Mm99999915_G1     (GAPDH) 
 
Analysis of results, q-PCR: Relative expression (mean +SEM) of genes in the 
wheel and morphine groups compared to sedentary control was calculated using 
the threshold cycles (Ct) for the genes of interest and the reference gene.  A one-
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way ANOVA confirmed that there was no significant effect of group in the 
expression level of the reference gene GAPDH in any of the brain regions tested 
(p>0.5).  Relative expression (fold change difference from control) was calculated 
with the formula: 2^(-(ΔΔCt) (Livak and Schmittgen, 2001).  ΔCt is the gene of 
interest Ct minus GAPDH Ct and ΔΔCt is ΔCt (gene of interest) minus the 
average ΔCt of the sedentary control group for the same gene within the same 
brain region. To determine if the changes in expression for the wheel access and 
chronic morphine groups were significant, Student’s t-tests compared the ΔΔCt 
values of the wheel access and chronic morphine groups to that of the no wheel 
control group.  
 
RESULTS 
 
Behavioral results: Morphine produced dose-dependent antinociception in 
the tail-flick procedure in all mice at all time points (Fig. 5.2).  At baseline there 
was no significant difference between the three groups in their antinociceptive 
sensitivity to morphine as determined by the ED50, [ED50 (95%CL)= 2.92 mg/kg  
(2.55-3.33), 3.50 mg/kg (3.07-4.00), 3.07 mg/kg (2.62-3.5), for wheel, morphine, 
and no wheel groups, respectively]. 
Fig. 5.2a shows that the morphine dose-effect curves for mice before and 
after six weeks of wheel access. At both time points, latency to respond 
increased as a function of morphine dose.  However, the dose-effect curve was 
shifted rightward at six weeks. The ED50 increased from 2.92 mg/kg  (2.55-3.33) 
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at 0 weeks to 5.36 mg/kg (4.88-6.40) at six weeks, yielding a potency ratio of 
1.98 (1.62-2.39). A similar pattern is seen in Fig. 5.2b.  5.5 days of twice daily 
injections of 56 mg/kg morphine produced a rightward shift in the morphine dose-
effect curve.  The ED50 increased from 3.50 mg/kg  (3.07-4.00) at 0 weeks to 
11.61 mg/kg (9.83-13.71) at six weeks, yielding a potency ratio of 3.22 (2.64-
3.93).   No such change in ED50 was apparent in mice control without wheel 
access (Table 1). Fig. 5.2c shows the second (post) dose-effect curve for each of 
the three groups.  A significant difference (non-overlapping confidence intervals) 
is seen between the ED50’s of all groups (see Table 5.1).  Specifically the dose-
effect curve of mice following 6 weeks of wheel access was shifted rightward 
compared to controls but was to the left of mice given chronic morphine.  Taken 
together, these data suggest that both chronic wheel access and chronic 
morphine shift the morphine dose-effect curve to the right. However, these shifts 
were greater following chronic morphine than following wheel access.  
 
qRT-PCR Results: Fig. 5.3 shows the relative expression (means +SEM) 
of proopiomelanocortin (POMC), proenkephalin (PENK), prodynorphin (PDYN), 
mu-opioid Receptor 1 (MOR1), and beta-arrestin 2 (ARRB2) in the hypothalamus, 
nucleus accumbens, striatum, and periaqueductal grey.  Gene expression 
(mRNA levels) is presented as fold change compared to control (without wheel 
access or chronic morphine).  A fold change of zero indicates gene expression in 
the experimental group is the same as the control group.  Positive values indicate 
up regulation and negative values indicate down regulation of a gene. Only four 
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changes were significant.  In the hypothalamus, POMC expression was 
significantly decreased in the both the wheel and morphine groups: t13=3.068 and 
t14=2.29 respectively, p<0.05.  In the PAG, MOR and Barr expression in the 
morphine group were significantly increased and decreased, respectively: 
t13=2.607and 2.90, p<0.05.  General patterns of increases and decreases are 
summarized in Table 5.2.  Taken together these data indicate that 1) six weeks 
of wheel access is sufficient to produce changes in gene expression and 2) the 
direction, if not magnitude, of these changes is the same as some of the changes 
following chronic morphine. 
 
Discussion: 
 
The experiments yielded two general findings.  Both chronic wheel access 
and chronic morphine 1) shifted the morphine does-effect curve to the right and 
2) altered gene expression. In the behavioral experiment, 6 weeks of wheel 
access and 5.5 days of twice daily injections of 56mg/kg morphine both produced 
rightward shifts in a morphine dose-effect curve. Such a shift is suggestive of 
tolerance to the antinociceptive effects of morphine. These data are consistent 
with previous reports that chronic wheel running in rats decreases sensitivity to 
multiple opioid agonists (Kanarek et al. 1998; Mathes and Kanarek 2001; Smith 
and Lyle, 2006; Smith and Yancey 2003).  However, it must be noted that the 
shift in the morphine curve was significantly greater in mice given chronic 
morphine as compared to those given access to running wheels. The behavioral 
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tolerance to morphine is likely due to desensitization of opioid receptors following 
agonist binding. Further, it is generally accepted that different mu opioid agonists 
differentially desensitize the opioid receptors.  In particular, morphine produces 
significant receptor desensitization but fails to promote efficient internalization 
and consequent resensitization (Bohn et al., 2004).  By contrast, DAMGO (a 
synthetic endorphin), triggers strong internalization (Connor et al., 2004). In 
general, it seems that the relative likelihood of opioids to induce endocytosis is 
inversely correlated with their potential to induce opioid tolerance (Williams et al., 
2013).  This cellular model may explain why chronic morphine produced a 
greater shift in the dose-effect curve.  Although the shift in the wheel access 
group was smaller, it is still a striking behavioral demonstration of running altering 
the function of the opioid system.  
 Following behavioral testing, the brains of the mice were collected for 
genetic testing.  The striatum, nucleus accumbens, hypothalamus and 
periaqueductal grey (PAG) were dissected from both hemispheres. Quantitative 
real time PCR was used to quantify changes in gene expression in the wheel and 
morphine groups as compared to control mice.  In general a complex picture 
emerged in which changes were sometimes similar and sometimes different 
between experimental groups and in comparison to published findings.   
The striatum and nucleus accumbens are both implicated in the 
reinforcing properties of opioids (Pettit et al.1984; Shippenberg et al. 1992; 
Spyraki et al. 1983; Stinus et al. 1989).  Although tolerance to the antinociceptive 
effects of morphine was examined here, chronic wheel access also has been 
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shown to decrease the rewarding properties of morphine as measured by 
conditioned place preference (Lett et al., 2002).  In the striatum, chronic 
morphine but not wheel access increased proenkephalin expression. This is in 
contrast to findings of Georges et al. (1999) and Turchan et al. (1997) who 
reported decreases following chronic morphine.  Prodynorphin expression 
increased in the morphine group, consistent with the findings of Turchan et al. 
(1997).  Expression in the striatum also increased in the wheel access group, 
which is consistent with Werme et al. (2000) who also reported increased striatal 
prodynorphin following cocaine.  In addition, POMC expression decreased in 
both the wheel and morphine groups in the stratum and in the wheel access 
group in the nucleus accumbens.  
 In the hypothalamus, the largest changes were decreases in expression of 
POMC in both the wheel access and morphine groups. This is consistent with 
finding from both Wei et al. (2009) and Garcia de Yebenes and Pelletier (1993) 
which report decreases in hypothalamic POMC following chronic morphine.  
Expression of the mu opioid receptor is generally not altered following morphine 
tolerance so the increase in expression in the both groups was surprising 
(Castelli et al., 1997).  An in vitro study from Zarnegar et al. (2006) reported 
increases in mu opioid receptor mRNA following exposure to the high affinity 
ligand DAMGO. In addition, hypothalamic mu opioid receptors play a complex 
role in the regulation of blood pressure and heart rate (Barnes et al., 2003; 
Feuerstein and Siren, 1988).  It is possible that up regulation of the receptor in the 
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hypothalamus is a response to the cardiovascular effects of chronic running 
rather than changes in neural circuitry directly mediating antinociception.  
 The most notable effect in the PAG was the decrease in expression of 
POMC and increase in the expression of the mu opioid receptor in both wheel 
and morphine groups.  Stimulation of the mu opioid receptors in the PAG is 
predominantly responsible for the analgesic activity of the opioids (Ossipov et al., 
2010).  Therefore it is interesting to see a reduction in expression of the 
endorphin precursor, POMC, and perhaps compensatory increase in receptor 
expression in animals that display antinociceptive tolerance.  Beta-arrestin 
expression was also decreased in chronic morphine exposed mice. Although this 
is somewhat surprising considering beta-arrestin’s role in receptor 
desensitization it is consistent with the findings of Fan et al. (2003) which 
reported a 40% decrease in mRNA in the PAG following chronic morphine. 
 Although the gene expression data are intriguing there are limitations to 
consider. To begin, changes were subtle, a less than 1-fold difference from 
baseline in all but one case.  It is possible that this reflects limits of the gross 
dissection method used. The genes of interest are all widely expressed in many 
brain regions and dissecting errors could have caused the inclusion of regions 
with opposing expression patterns (McDonald and Lambert, 2005). It is also 
worth noting that the periaqueductal grey dissection likely included parts of the 
locus coeruleus.  Although qRT-PCR does allow for subtle changes to be 
measured, it is simply a measure of mRNA in the sample.  Changes in mRNA 
may not be perfectly correlated with changes in protein levels and certainly do 
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not address the location of protein within the cell.  Future experiments using 
Western blots and in situ hybridization could potentially address these questions.  
Finally, since mRNA levels can change quite rapidly, the changes observed 
could reflect how different groups responded to the morphine and the process of 
obtaining of the dose-effect curve rather than differences that arose over the six-
week period.      
Despite limits, these data do support the hypothesis that wheel access 
can produce changes to the opioid system that have both behavioral and cellular 
consequences. However, it is clear that much more research is necessary to fully 
characterize and understand the significance of the cellular changes following 
aerobic exercise.   
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TABLES 
 
Table 5.1. Tail-flick ED50 values and potency ratio for each group.      
 
Week 0 
ED50 (95%CL) 
Week 6 
ED50 (95%CL) 
Potency Ratio 
(95%CL) 
Wheel access 
2.92 
(2.55-3.33) 
5.36 
(4.48-6.40) 
1.98 
(1.62-2.39) 
56mg/kg morphine 
3.50 
(3.07-4.00) 
11.61 
(9.83-13.71) 
3.22 
(2.64-3.93) 
No wheel 
3.07 
(2.62-3.5) 
2.76 
(2.40-3.19) 
0.91 
(0.74-1.11) 
 
Potency ratios greater than 1 are considered significant. ED50 values with 95% 
confidence limits that do not overlap are considered significantly different 
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Table 5.2. Significant increases and decreases in gene expression as compared 
to control.  
  Wheel Morphine 
 
Striatum 
proenkephalin   
prodynorphin   
POMC   
MOR1   
beta-arrestin   
    
 
Nucleus 
accumbens 
proenkephalin   
prodynorphin   
POMC   
MOR1   
beta-arrestin   
    
 
Hypothalamus 
proenkephalin   
prodynorphin   
POMC * * 
MOR1   
beta-arrestin   
    
 
PAG 
proenkephalin   
prodynorphin   
POMC   
MOR1  * 
beta-arrestin  * 
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FIGURES 
 
Sagittal View: 
                                
 
      Coronal Section 1    Coronal Section 2 
                            
      
                     Coronal Section 3 
      
Fig. 5.1 Dissections. Starting from a sagittal orientation, four cuts are made to 
produce three coronal sections.  Additional cuts are made, as indicated, to 
dissect out the striatum (STR), nucleus accumbens (NAC), hypothalamus (HYP), 
and periaqueductal grey (PAG) from coronal sections 1, 2 and 3. 
 
  1   2   3 
103 
 
 
Fig. 5.2 Six weeks of wheel access and chronic morphine both 
produced rightward sifts in the morphine dose-effect curve compared to 
pre exposure and controls. Morphine treatment consisted of 5.5 days of twice 
daily injections (56 mg/kg, s.c.).  The dose-effect curves for morphine (0.32-32 
mg/kg) were assessed before and after wheel access (A) and chronic morphine 
(B) using the tail-flick. Tail-flick latencies of mice without wheel access were also 
compared to those of mice following wheel access and morphine (C). Mean 
latencies to respond (±SEM ) are presented as % maximum possible effect 
(%MPE).  N=7-8.
                   
Fig. 5.3  Fold change in gene expression as compared to control mice with no wheel access. Changes in gene 
expression are calculated using the ΔΔCt method with GAPDH as the reference gene and mice without wheel access as 
the control group.  Fold change from control (0) is presented as the group mean. *=significant change from control 
(p<0.05) 
1
0
4
 
   
Chapter 6 
General Discussion  
 
EXPERIMENTAL RESULTS 
The experiments included in this dissertation were designed with two 
goals in mind. The primary goal was to examine the effect of running wheel 
access on spontaneous morphine withdrawal, as well as to investigate possible 
mechanisms of the effect.  A secondary goal was to assess the use of thermal 
sensitivity as a measure of spontaneous morphine withdrawal.  
 This second goal, the validation of procedure, was the aim of the first set 
of experiments described in Chapter 2.  The data indicate that thermal sensitivity 
provides a sensitive and replicable measure of spontaneous morphine 
withdrawal.  This is consistent with previous research in both humans and 
animals reporting heightened sensitivity to thermal stimuli following termination of 
a regimen of morphine administration (Angst et al. 2003; Compton et al. 2003; 
Dunbar and Pulaj 1998; Rubovitch et al. 2009; Sweitzer et al. 2004). 
The current experiments are the first to systematically characterize and 
validate the use of thermal sensitivity as a measure of spontaneous morphine 
withdrawal in mice. Specifically, latency to respond on the hot plate at multiple 
temperatures was assessed at multiple time points throughout the first week 
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following the cessation of 5.5 days of twice-daily injections of 30, 56 and 100 
mg/kg morphine. The greatest change in response latency during the first days of 
the withdrawal period was seen in mice that were administered 56 mg/kg 
morphine.  Latencies returned to baseline by one week.  Demonstration of a 
dose dependent response and recovery to baseline are critical for the validation 
of thermal sensitivity as a measure of withdrawal. In addition, data from saline-
treated control groups confirmed that neither repeated testing nor time of day had 
significant effects on the withdrawal measures. In conclusion, response latencies 
on the hot plate showed little variability within groups and little effect of repeated 
testing, maximizing sensitivity to subtle changes in withdrawal severity. This 
suggests that the thermal sensitivity procedure is optimal for assessing subtle 
effects of medications and environmental interventions throughout spontaneous 
opioid withdrawal.  
The second section of Chapter 2 found that buprenorphine, a partial opioid 
agonist that is often used in the treatment of withdrawal, attenuated the observed 
increase in thermal sensitivity. It will be of interest to further enrich the 
pharmacological validity of this assay using other opioid drugs.  Additionally, it 
may be of interest to develop withdrawal assays that utilize other measures of 
hypersensitivity such as the tail-flick or von Frey tests and examine those during 
spontaneous withdrawal.  Ultimately, it will be necessary for this assay to be 
replicated in other labs and optimized for other strains of mice.   
The thermal sensitivity procedure was used to examine withdrawal 
throughout the majority of the following experiments. Chapter 3 tested the 
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primary hypothesis of this dissertation: The severity of spontaneous morphine 
withdrawal, as measured by hypersensitivity to a thermal stimulus, is reduced in 
mice that are given access to running wheels in their home cages.  Thermal 
sensitivity was measured on the hot plate at baseline and at 8, 24, 32, and 48 
hours after the final morphine injection to assess withdrawal severity.   
Thermal sensitivity was significantly attenuated in mice with access to a 
running wheel during the withdrawal period. Furthermore, in mice with wheel 
access, thermal sensitivity was fully returned to control levels. That is, thermal 
sensitivity in mice with access to running wheels was identical to that observed in 
saline-treated mice, not in withdrawal.  Importantly, wheel access alone (saline + 
wheel) had no effect on hot plate responding.  Thus, it would be of interest to 
further explore the effect of wheel access following additional maintenance doses 
of morphine and at longer time points.  Additionally, these experiments are 
limited by the use of a single behavioral measure of withdrawal. Future 
experiments should test whether wheel running can attenuate the many other 
measures of morphine withdrawal used in rodents. Despite limitations, these data 
do support the hypothesis that wheel running can reduce the severity of 
spontaneous morphine withdrawal.   
The majority of prior animal literature considering wheel running and drugs 
of abuse (amphetamine, heroin, alcohol, and morphine) has focused on 
reductions in drug taking and drug seeking in rats with wheel access (Hammer et 
al., 2010; Kanarek et al., 1995; Lett et al., 2002; Smith and Pitts, 2012).  To the 
best of our knowledge, only one other group has published data on the effect of 
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wheel running during spontaneous opioid withdrawal. Miladi-Gorji et al., (2011, 
2012) reported reductions in cognitive deficits and anxiety during spontaneous 
morphine withdrawal in rats. 
To date, no studies have been published on the effect of aerobic exercise 
during morphine withdrawal in humans. However, it is known that, during periods 
of abstinence, aerobic exercise can decrease the desire for alcohol and cannabis 
and reduce symptoms of nicotine withdrawal (Buchowski et al., 2011; Taylor and 
Ussher, 2005; Taylor and Katomeri, 2007; Ussher et al., 2004). We feel that the 
current findings are consistent with and provide an important addition to the 
literature.   
Opioid dependence is often, and effectively, treated with substitution by 
methadone or buprenorphine (Connock et al. 2007; Strain et al. 2011; Tetrault 
and Fiellin 2012).  Furthermore, studies from the Kanarek and Smith laboratories 
suggest that, in rodents, wheel running can alter the opioid system as measured 
by changes in morphine’s potency (Kanarek et al., 1998; Mathes and Kanarek, 
2001; Smith and Yancey 2003; Smith and Lyle, 2006). Thus, I speculate that the 
behavioral effects of wheel access are, at least partially, related to wheel 
running-induced release of endogenous opioids that are able to reduce 
withdrawal severity in much the same way as exogenous opioid agonists can 
reduce withdrawal symptoms.  
The second section of Chapter 3 provides support for the possibility that 
the observed effects of wheel access during withdrawal are dependent on activity 
of the opioid system.  Specifically, pretreatment with naltrexone, a high affinity 
109 
 
mu and kappa opiate receptor antagonist, blocked the effect of wheel access in 
mice 32 hours into spontaneous morphine withdrawal.  Twenty-four hours later, 
following the metabolism of naltrexone, a full recovery of the effect of wheel 
access was observed. Importantly, naltrexone had no effect on thermal sensitivity 
in mice that were not in withdrawal or did not have wheel access.  Although these 
data are intriguing, it will be of interest to consider the effect of multiple doses of 
naltrexone given at various time points.  Furthermore, though these data support 
a role of the opioid system in the observed behavioral effect, they in no way 
prohibit a role for other mechanisms.   
 The experiments of Chapter 4 provide one approach to addressing the 
question of how wheel access impacts the opioid system.  Specifically they test 
the hypothesis that the use of the wheel, not simply access to a wheel, is 
necessary for the behavioral effect seen during withdrawal. The current 
experiments indicated that a locked wheel (access without use) was insufficient 
to replicate the effects of an unlocked wheel on thermal sensitivity during 
withdrawal. This finding, that access to a locked wheel did not produce the same 
behavioral effects as access to an unlocked wheel, is consistent with the majority 
of published findings (e.g. Burghardt et al., 2004; Devaud et al., 2012; 
Pietropaolo et al., 2006; Sartori et al., 2011; Zlebnik et al., 2010 and 2012). 
Although these data do support the hypothesis that the ability to run on the 
wheel is a critical part of the wheel effect, a clear correlation between the amount 
of running and the magnitude of effect was not apparent.  This finding was 
contrary to our hypothesis that thermal sensitivity would be lowest in individual 
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mice that ran the most. This hypothesis was based on two assumptions 1) that 
wheel access acts like a pharmacological intervention such that larger “doses” 
produce greater effects and 2) that wheel revolutions are an accurate measure of 
aerobic exercise.  A few studies do support the assumption that the intensity of 
aerobic exercise is positively correlated with greater release of beta-endorphin 
and other opioid peptides (Goldfarb et al., 1990; Mehl et al., 2000; Mougin et al., 
1988).  That said, it is quite possible that there are individual differences in the 
“dose” of running necessary to produce a maximal effect such that running 
beyond a certain amount fails to produce greater effect.  This is somewhat 
supported by the finding that, despite differences in wheel revolutions, there was 
little variation in thermal sensitivity (which was fully returned to that of saline-
treated controls).  
In addition, it is possible that the measure of the “dose” of exercise was 
confounded by variations in the tension of wheels over time and between mice or 
by the way the wheels were used (multiple short or fewer long bouts of use within 
each period).  It would be of interest to further explore individual differences in 
wheel use to identify which features (amount, amount up to a ceiling, intensity, 
etc.) are correlated with maximal behavioral effect.  It seems reasonable to 
speculate that, once variations in the wheel and wheel use are controlled for, 
there is a strong ceiling effect such that a correlation emerges below a certain 
amount of running but once a certain level is reached (which may differ between 
individuals) a full behavioral effect is achieved. The complexity of the relationship 
between individual running and magnitude of behavioral effect may explain why 
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so few papers that include wheel use also report correlation data.  In fact, the 
Smith laboratory is one of the few groups to report positive correlations (Smith 
and Lyle, 2006 and Smith et al., 2008) and yet, in a recent paper, they 
acknowledge a failure to see a correlation between heroin self-administration and 
wheel running during the study (Smith and Pitts, 2012).  Finally, the lack of 
correlation does not diminish the significance of the effects of wheel access 
during spontaneous withdrawal. 
The second section of Chapter 4 provided comparison between the effect 
of wheel access and that of an alternate environmental intervention, group 
housing.  The current experiment indicated that group-housed mice only showed 
significant attenuation of morphine withdrawal at 8 and 24 hours.  Although this 
finding is in contrast with Coudereau et al. (1997b) and Broseta et al. (2005), who 
reported that opioid withdrawal was attenuated in single- rather than group-
housed mice, significant methodological differences make direct comparison of 
results difficult.  In order to fully characterize the effects of group housing on 
morphine withdrawal, further studies are necessary to examine a range of 
parameters (length of isolation/group housing, number of animals per cage, drug 
treatment of group-housed peers).   
In conclusion, the experiments of Chapter 4 replicate the finding from the 
previous chapter that wheel access can reduce the severity of morphine 
withdrawal as measured by thermal sensitivity. Although this effect requires 
access to an unlocked wheel, there is not a simple correlation between amount 
of running and attenuation of withdrawal. Finally, group housing, an alternative 
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form of enrichment, produced an intermediary effect between that of locked or no 
wheels and unlocked running wheels. Interestingly, although the dependent 
measure was different, studies from Burghardt et al. (2004) and Pietropaolo et al. 
(2006) also found that group housing produced an intermediate effect on 
cognition and anxiety between locked and unlocked wheel access. 
The final experiments used genetic techniques to investigate a secondary 
behavioral effect of wheel running.  Specifically, extended access to running 
wheels shifts the antinociceptive potency of morphine in rodents (Kanarek et al. 
1998; Mathes and Kanarek 2001; Smith and Lyle, 2006; Smith and Yancey 2003). 
This behavioral effect was used because it is a simple and established model 
that demonstrates the consequence of wheel running on the opioid system. The 
behavioral data of Chapter 5 demonstrate that cross-tolerance between six 
weeks of wheel use and acute morphine can develop in mice as measured by a 
rightward shift in the morphine dose-effect curve. This shift, though significant, 
was less than the potency shift seen following traditional tolerance induced by 
chronic morphine (5.5 days of twice daily 56 mg/kg injections).   
The second section of Chapter 5 used quantitative real-time PCR to 
assess changes in gene expression that might underlie the behavioral effect.  In 
general, both chronic wheel and chronic morphine exposure produced changes 
in gene expression, in comparison to controls.  However, parallel changes 
between groups were minimal and not consistent within a particular gene or brain 
region. This is not surprising because, although both interventions produce 
similar changes in one behavior, it is quite reasonable to expect that the body 
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responds and adapts differently to endogenous versus exogenous changes.  For 
example, one striking finding was the large increase in expression of the mu 
opioid receptor in the hypothalamus of the wheel access mice. This change may 
be correlated with the measured behavior considering that limited evidence 
suggests that DAMGO, a synthetic opioid peptide, can also increase expression 
(Zarnegar et al., 2006).  However, considering the role of the hypothalamus in 
regulation of the cardiac system, it seems likely that this is an example of one of 
the many effects of wheel running largely unrelated to the opioid tolerance and 
withdrawal that these experiments are concerned with (Barnes et al., 2003; 
Feuerstein and Siren, 1988).  It is also worth noting that the hypothalamus plays a 
major role in the regulation of appetite and stress response, both of which are 
affected by aerobic exercise.   
That said, expression in the periaqueductal grey of the mu opioid receptor 
and POMC, the precursor mRNA for its ligand, endorphin, were both changed, in 
a consistent manner, in the wheel and morphine groups. These genes are of 
interest considering that stimulation of the mu opioid receptor in this region is 
predominantly responsible for the antinociceptive potency of opioids (Ossipov et 
al., 2010).   
In future experiments, it will be important to over or under express genes 
in order to determine whether the observed expression changes following wheel 
running are necessary and/or sufficient for a shift in morphine potency.  In 
addition, future studies should measure changes in protein, as opposed to mRNA 
level, (Western blots) and consider more precise spatial data (in situ 
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hybridization). Despite limitation, this data set does provide novel data on, and 
direct comparison between, the expression of a range of genes associated with 
the opioid system in wheel and morphine exposed mice.  Further, taken as a 
whole, mice with wheel access exhibited both a reduction in morphine sensitivity 
(tolerance) and a general down regulation of opioid system genes. 
 
GENERAL LIMITATIONS AND FURTHER EXPERIMENTS 
The current experiments found that access to a running wheel can reduce 
the increase in thermal sensitivity seen during spontaneous morphine withdrawal 
in mice. As with all experiments, results often lead to more questions than 
answers. One major limitation of the current research was the use of single 
measure of withdrawal. Thus, it would be of great interest to investigate the effect 
of wheel running in any of the many other assays of spontaneous withdrawal. 
Although the most common method used to assess opioid withdrawal in 
rodents is a global scale, such scales are best suited to assess the severe 
withdrawal precipitated by opioid antagonists (Gellert and Holtzman, 1978; Kest 
et al., 2002).  When used to assess spontaneous withdrawal, symptoms tend to 
appear with too much variability (jumping and paw flutters) or at such low rates 
(shakes, diarrhea) that assessing change, as opposed to presence/absence, of 
withdrawal is difficult (Papaleo and Contarino, 2006; unpublished pilot data).  
Miladi-Gorji et al. (2011, 2012) did report that wheel running had positive effects 
on measures of cognition (Morris water maze) and anxiety (elevated plus maze 
and light/dark box) during spontaneous withdrawal. However, these experiments 
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only considered a single dose of morphine and single time point during 
withdrawal. Thus, it would be interesting to assess the impact of wheel running 
on the cognitive effects of withdrawal.  In addition, a few studies have reported 
reductions in intracranial self-stimulation (ICSS) during morphine withdrawal 
(Altarifi and Negus, 2011; Easterling and Holtzman, 1997; Liu and Schulteis, 
2004; Schaefer and Michael, 1983). ICSS responding during spontaneous 
withdrawal appears to be sensitive and stable through repeated testing and could 
be an ideal measure to assess the effect of wheel access.  
 Although the experiments described here provide strong behavioral data 
on the effect of wheel access, they are limited in their ability to address why or 
how running has its effects. One line of thinking posits that running acts through 
activation of the opiate system. This hypothesis of mechanism is most directly 
addressed in the experiments of Chapter 3, which found that naltrexone 
pretreatment could temporarily block the effects of wheel access, although a full 
range of doses and time points were not tested.  Since antagonism of the opiate 
system is sufficient to disrupt the behavioral effect, it would be of interest to test 
whether enhancement of the system could potentiate the effects.   
The drug RB101, an enkephalinase inhibitor that increases synaptic levels 
of beta-endorphins, enkephalins and dynorphins, has previously been shown to 
decrease spontaneous morphine withdrawal in rats (Ruiz et al., 1996; Thanawala 
et al., 2008).  If wheel running reduces withdrawal severity through the 
substitution of morphine with endogenous opioids, then RB101 should be able to 
potentiate wheel effects, especially at time points or following morphine doses 
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where wheel effects are more subtle.  
Although this line of thinking is built on the idea that wheel running has its 
effects through the opiate system, it does not exclude the possibility of additional 
pathways of action.  Signaling via the hypothalamic peptide galanin is one 
particularly intriguing alternative. The galanin receptor, GalR1, is expressed 
throughout the brain including in regions implicated in opioid withdrawal, the 
locus coeruleus and periaqueductal grey (Burgevin et al., 1995).  Systemic 
administration of the galanin receptor agonist, galnon, has been shown to 
attenuate morphine withdrawal in mice.  Furthermore, targeted expression of 
galanin to noradrenergic neurons of the locus coeruleus is sufficient to attenuate 
morphine withdrawal signs (Zachariou et al., 2003).  In the locus coeruleus, 
galanin is known to decrease firing rates of norepinephrine releasing neurons.  
(Pieribone et al., 1995; Seutin et al., 1989; Sevcik et al., 1993). It is hypothesized 
that galanin attenuates morphine withdrawal by decreasing the release of 
norepinephrine in the locus coeruleus through activation of its Gi coupled 
receptors which decrease cAMP in a manner similar to that of prior opiate 
receptor activation (Zachariou et al., 2003).  
 Though no research is published on running induced changes in galanin 
during withdrawal, it has been shown that wheel access in rodents can increase 
galanin expression in the locus coeruleus, leading to suppression of neuronal 
activity and adaptive responses to stress (Sciolino and Holmes, 2012; Sciolino et 
al., 2012).  Considering these two lines of study, we hypothesize that wheel 
running may decreases the severity of morphine withdrawal by (also) triggering 
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the release of galanin in the locus coeruleus.  
In addition to probing the cellular mechanisms by which wheel running 
produces behavioral effects during withdrawal, it would also be of interest to 
identify the brain regions and circuits that play a role in these effects. To begin, 
there is extensive research implicating both the locus coeruleus and 
periaqueductal grey in opioid withdrawal (e.g. Christie et al., 1997).  However, 
data from Chapter 5 highlights wheel access induced changes in multiple other 
brain regions as well. Considering the widespread effects of wheel running on the 
brain, it is likely that many brain regions play a role and it may be difficult to 
disrupt the effect of wheel running without disrupting the expression of withdrawal.  
Finally, it is possible that wheel running attenuates different signs of withdrawal 
via different mechanisms. For example, attenuation of thermal sensitivity (a pain 
response) may be mediated by endogenous opiate activity in the PAG while 
running induced decreases in anxiety as shown by Miladi-Gorji et al. (2011) are 
mediated by galanin activity in the locus coeruleus.  
 
CONTRIBUTIONS AND SIGNIFICANCE 
The first contribution of this dissertation is the development and validation 
of thermal sensitivity as an assay of spontaneous morphine withdrawal in mice 
(Balter and Dykstra, 2013).  Currently, there are many assays of morphine 
withdrawal in rodents, each with strengths and weaknesses, ranging from 
somatic symptom scales to conditioned place aversion and disrupted operant 
responding.  Thermal sensitivity is a valuable addition because 1) it provides a 
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reliable preclinical model for the hyperalgesia seen in humans and 2) is optimal 
for assessing subtle effects of chronic interventions during spontaneous 
withdrawal.  
 The second contribution of this work is the finding that aerobic exercise 
can reduce withdrawal severity in mice.  Although it certainly will be of interest to 
fully explore the mechanisms by which wheel access attenuates withdrawal, the 
translational potential of the effect should not be ignored.  To date, few studies 
have been published on the effect of exercise in the treatment of substance 
abuse in humans. That said, this is an area of active research.  Dr. Richard De 
La Garza at Baylor University and Dr. Richard Rawson at UCLA both have NIDA 
funded grants to investigate the ability of exercise, in an inpatient setting, to 
improve outcomes of treatment for cocaine and methamphetamine dependence, 
respectively. Dr. Nancy Petry at the University of Connecticut has developed an 
outpatient procedure that uses contingency management to encourage exercise.  
She is currently funded to study the effects of this procedure on cocaine users.   
Looking forward, it will be of great interest to study the clinical benefits of aerobic 
exercise, in combination with current interventions, in the treatment of opioid 
dependence.  
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